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Abstract 
Back Ground    Chitosan as a natural polymer has been fabulated into a number of formulations 
such as films, hydrogels and particles based on its excellent properties such as biodegradable, 
biocompotable, bioadhesive, permeartion-enhancement, antibiotic, antitumor etc. properties. Among 
them, chitosan microparticles found a lot of applications in pharmaceutics such as vaccine delivery, 
mucosal delivery and gene delivery, etc. Down to the nanoscale, chitosan nanoparticles have more 
attractive properties more than that of chitosan microparticles, which further widen the applications of 
chitosan particles in biomedicine and biopharmaceutics.  
Objective of this Thesis   This thesis is aimed to prepare chitosan micro or nanoparticles to delivery 
proteins. 
What are the questions this thesis attempted to solve?   1) What are the proper preparation 
conditions of chitosan micro or nanoparticles? 2) How does the pH value affect the formation and 
protein encapsulation of chitosan nanoparticles? 3) How to overcome the burst release of chitosan 
nanoparticles? 4) How to overcome the aggregation disadvantage in the contritional preparation 
process of TPP-gelated chitosan microparticles? 5) How to construct a composite particles system to 
realize the sustainable release of proteins? 
What are the methods used in this thesis?   1) ionotropic gelation method to prepare chitosan 
nanoparticles 2) Emulsification-coacervation (NaOH) method to prepare chitosan microparticles 3) a 
polyelectrolytes coacervation method to prepare chitosan-BSA complexes 4) a microemulsion involved 
emulsification-coalescence method to prepare TPP-gelated chitosan microparticles 5) a nanoparticles 
encapsulation method to prepare composite particles. 
Results and Conclutions  1) the effect of preparation parameters on the properties of chitosan 
nanoparticles: 1a) the concentration of chitosan has no siganificant effect on particles yield, positively 
associated with particles size, size distribution, positively associated with BSA encapsulation efficiency 
in a specific concentration range; 1b) the mass matio of chitosan to TPP negatively associated with 
particles yield, positively associated with particle size and size distribution, negatively associated with 
BSA encapsulation efficiency; 1c) the concentration of BSA has no significant effect on particles yield, 
particle size or size distribution, negatively associated with BSA encapsulation efficiency in a specific 
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concentration range. 2) a chitosan polymer chain conformation related mechanism is proposed through 
the study of the effect of pH value on the formation and BSA encapsulation of chitosan nanoparticles. 3) 
the most homogeneous and smooth chitosan particles could be obtained at the parameters of: 2% (m/v) 
chitosan solution, 2/10 w/o volume ratio, 4% Span 85 as susfactant, 5 Krpm homogenization speed and 
3 times addition of NaOH solution as a coacervation agent. The obtained particles have a mean 
diameter of 9.4±1.9 μm. The BSA loading test found that dispersed particles only could be obtained 
below the BSA concentration of 0.5% under above mentioned parameters. 4) a noval polyelectrolytes 
complex formed by TPP and BSA is obtained attempted to solve the burst release effect of chitosan 
nanoparticles. 5) a microemulsion involved emulsification-coalescence method is used to overcome the 
aggregation problem of TPP-gelated chitosan microparticles. 6) a chitosan nanoparticles encapsulated 
PLA composite particles are successfully constructed.  
What is new in this thesis?   1) to study the formation mechanism and protein encapsulation of 
chitosan nanoparticles through the study of the effect of pH value on their properties and propose the 
role of chitosan polymer chain conformation during this process, 2) a noval TPP-BSA polyelectrolytes 
complex is obtained base on the purpose to overcome the burst release effect of chitosan nanoparticles, 
3) apply emulsification-coalescence method in which a microemulsion of cross-linking agent-TPP is 
used to solve the aggregation problem of TPP-gelated chitosan microparticles, 4) propose a chitosan 
nanoparticles encapsulated PLA composite particles to control the release of proteins. 
Where is the study of this thesis in the field?   1) Chitosan nanoparticles have been 
extensively investigated in the past few years and the factors which can affect the properties of chitosan 
nanoparticles have been well documented as well. This thesis provides the evidence from a new side to 
understand the formation and protein encapsulation mechanisms of chitosan nanoparticles. 2) New and 
highly effective methods have been proposed by others to prepare protein loaded chitosan 
microparticles such as sieving and microfluidic methods which can reproduceably scale up the 
production of monodispersed chitosan microparticles. This thesis just solved a technique problem in the 
conventional preparation process of TPP-gelated chitosan microparticles. 3) The proposed TPP-BSA 
polyelectrolytes complex could be an alternative route to overcome the burst release effect of chitosan 
nanoparticles. 4) The proposed chitosan nanoparticles encapsulated PLA composite particles is one of 
the solutions among other composite particles proposed by others.  
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 Chapter 1 Introduction 
Tissue engineering aims at the repairing and restoring damaged tissue function employing three 
fundamental “tools”, namely cells, scaffolds and growth factors which, however, are not always 
simultaneously used [1]. There are four fundamental technologies or methodologies that are necessary 
for tissue engineering. They are preparing artificial scaffold for proliferation and differentiation of cells, 
drug delivery system (DDS) to preserve the biological activity of growth factors and control their 
release, efficient isolation and proliferation of cells, a physical barrier to protect transplanted cells and 
the area to be regenerated from immunological attack and fibroblast infiltration [2]. Some DDSs such 
as hydrogel, microfluidic system, viral or cellular carriers, and nano- or micro-carriers have been 
successfully prepared to induct the regeneration of tissues and organs by the controlled release of 
various biologically active growth factors. Specific DDS has its own advantages and disadvantages 
respectively. For insistence, hydrogel release system has the advantage of easy fabrication and mass 
productability, but may have the disadvantage of poor regulation of release profile and activity loss of 
molecules. Chitosan based micro- or nano- particles as particulate drug delivery system are mainly 
discussed in this thesis. In order to control the release profile of growth factors in a bioengineering 
scaffold, CSMPs are prepared in this thesis. Therefore, the preparation methods and biomedical 
application of CSMPs are reviewed in the third section of this introduction part.  
Drug delivery formulations have gained huge support from emerging nanotechnology. 
Nanotechnology, which is still not a mature technology and thus, more appropriately called 
nanoscience, usually refers to research at the scale of 100 nm or less [3]. Nanotechnology has been 
evolving tremendously in last few decades and made enormous impact on many other research scopes. 
In the human health field, the introducing of nanotechnology gave rise to a novel concept 
‘nanomedicine’. In definition, nanomedicine is the process of diagnosing, treating, and preventing 
disease and traumatic injury, relieving pain, and preserving and improving human health, using 
molecular tools and molecular knowledge of the human body [4]. Numerous nanomedicine research 
activities have been dedicated to drug delivery study. Many of the current ‘nano’ drug delivery systems 
which are remnants of conventional drug delivery systems that happen to be in the nanometer range, 
such as liposomes, polymeric micelles, nanoparticles, dendrimers, and nanocrystals. Due to the 
advantages of nanoscaled size, these nanovehicles are capable of overcome tissue barriers in human 
body, reach specific disease sites and remain there longer to realize larger bioavailability. Some of them 
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are even able to deliver loaded package to specific organelles. Even so, this research field develops so 
fast that all above mentioned nanocarriers are already called as ‘first generation’ nanomedicine. 
Conjugated with special target ligands, such as antibodies, peptides or other adaptors, these 
nanocarriers are able to target specific cell subsets. Functionalized with various functional groups, 
some of they become multifunctional nanocarriers, for instance, both capable of imaging and treating, 
both thermal and pH responsible, and so on. In addition, various nanocarriers such as organic and 
inorganic nanoparticles are combined to exert multiple functions. All of these refined mono or multiple 
nanocarriers could be termed as the second generation nanomedicines or even are further subdivided to 
be ranked as more advanced generation. In this thesis, chitosan nanoparticles (CSNPs) are prepared for 
delivering protein drugs. Therefore, the preparation methods and biomedical application of CSNPs are 
introduced in this chapter.  
1.1 Particulate Drug Delivery System 
  In the past few decades, more and more research work has been conducted on particulate drug 
delivery systems. Particulate systems such as microparticles and nanoparticles have been widely used 
to delivery a wide range of macro or small molecules to improve their pharmacokinetic and 
pharmacodynamic in human body. As drug delivery systems, they have the advantages of protecting 
drug from quick digestion and damage by body fluid, localizing at desired spots and releasing 
encapsulated drugs. These advantages remarkably enhance drug bioavailability and efficacy, reduce 
undesired side effects, and consequently improve patients’ comfort and compliance. 
1.1.1 Microparticles  
Microparticle, also called as ‘microsphere’ or ‘microcapsule’ have many applications in medicine. In 
most cases, microparticles are used as drug carriers to deliver drug to the areas of interest and slowly 
release encapsulated drug over a desired period of time to maintain an effective local drug 
concentration. Microparticles also has novel application in the foods, medical devices, chemical 
coatings, personal health testing kits, sensors for security systems, biochemical sensors water 
purification units for manned space craft, and high throughput screening techniques[5]. In this chapter, 
the application of microparticles will be overviewed only on the aspect of drug delivery. 
Immune Adjuvants 
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Recently microparticles have been well developed as effective immune adjuvants. In order to realize 
a strong and lasting immune response, many vaccination formulations need the assistance of adjuvants 
since many antigens couldn’t produce sufficient immune responses themselves. Generally 
microparticles could serve as immune adjuvants via enhancing and/or facilitating the uptake of antigens 
by antigen-presenting cells (APCs) such as dendritic cells (DCs) or macrophages; storing and 
controlling the release of loaded antigens, consequently increasing the availability of antigens to the 
immune cells; induce multiple immune responses by loading antigens combination; protecting sensitive 
antigen molecules from the degradation effect of surround environment and so on [6]. To date, many 
polymers [7], copolymers [8], and lipids [9] have been applied to produce microparticulate carriers of 
many kinds of antigen. Several important factors like particle size, morphology, particle surface 
properties, antigen loading and release kinetics of microparticles dramatically affect the induced 
immune responses in the sense of antigen stability, antigen release, particle interaction with APCs, 
antigen presentation and processing by APCs [10].  
Ocular Drug Delivery 
Microparticles have also been applied as ocular drug delivery system. The major objective of ocular 
therapeutics is to maintain sufficient drug concentration and residence time at the site of action. 
Whereas, the protective mechanisms such as rapid turnover, lacrimal drainage, reflex blinking, and 
drug dilution by tears lead to poor drug availability and permeation through corner. Considering the 
efficiency of conventional ophthalmic formulations like eye drops, suspensions, and ointments are 
badly compromised by the above mentioned physiological barrier, various modern approaches have 
been proposed. For instance, in situ gel, ocuserts, nanosuspension, microparticles, nanoparticles, 
liposomes, niosomes, and implants improve the ophthalmic bioavailability of the drugs and controlled 
the release of the ophthalmic drugs to the anterior segment of the eye [11]. Among them, Microparticles 
extend precorneal residence time, which leads to continuous and sustain release of the drug and 
consequently improve ocular bioavailability of the drug and reduced dosing frequency. Some natural or 
synthetic materials with good biodegradability, biocompatibility and bioadhesion like gelatin [12], 
chitosan [13] and hyaluronate esters [14] have been used to prepare these microparticles. 
Pulmonary Drug Delivery 
Pulmonary drug delivery (PDD) has several advantages which the pulmonary route offers over the 
others routes of drug administration, i.e. reduces first-pass metabolism or gastrointestinal degradation 
(such as proteins and peptides). In addition, less invasiveness and lower side effects of pulmonary 
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administration increase patient compliance and reduce systemic exposure. However, PDD may has 
limitations due to a series of defenses of respiratory tract against inhaled materials such as mucociliary 
clearance, alveolar macrophages clearance, enzymatic metabolism and low permeability. All these 
barriers could lead to insufficient drug local concentration or bioavailability and consequently frequent 
drug administration is required. Particulate drug carriers such as liposomes, microparticles and 
nanoparticles can be/have been used to improve the therapeutic index of new or established drugs by 
modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity 
[15]. 
1.1.2 Nanoparticles  
Nanotechnology has been vastly applied in fiber and textiles, agriculture, electronics, forensic 
science, space and medical therapeutics [16]. The application of nanotechnology in medicine gave the 
birth of a new concept—nanomedicine. To date, many nanomedicine formulations have been developed, 
i.e., nanoparticles, nanocapsules, micellar syatems and dendrimers [16]. These nanoscaled formulations 
improve drug bioavailability, prolong drug in vivo circulating half-live and decrease drug size effect as 
a DDS. In addition, nanomedicine has specific advantages due to its nanoscaled size and targeted drug 
delivery is one of them.  
Targeted Drug Delivery 
The targeted drug delivery of nanomedicine could be achieved through passive or active targeting 
route. Generally the passive targeting is based on the enhanced permeability and retention (EPR) effect 
of the physiology of diseased tissues such as tumor or inflammation tissues. Whereas, nanomedicines 
have a longer EPR effect in tumor tissues for weeks than that in inflammation sites for few days. This 
could be contributed to the lymphatic drainage system is still operative in inflammation sites, thus 
swelling may dissipate in a matter of a few days. While, cancer is like inflammation that never ceases 
but grows [17], which results in a consequential long period of EPR effect. The EPR effect has been 
applied to develop a number of passively targeting nanocarrieres and one example is PEGylatyed 
liposome-Doxil which encapsulates an antitumor drug—doxorubicin. It has shown a long drug 
retention, circulation time and 6 times more effective in comparison with free doxorubicin [18].  
On the other hand, active targeting requires the conjugation of receptor specific ligands to realize 
diseased sites targeting. It could be achieved by molecular recognition of the diseased cells by various 
signature molecules overexpressed at the diseased site either via the ligand-receptor, antigen-antibody 
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interactions or by targeting through aptamers. Thus, specific ligands-conjugated nanocarriers could 
overcome the physiological barriers and access different tissues followed by an efficient cellular uptake 
and intracellular internalization. Kocbek et al. [19] reported a monoclonal antibody-conjucated PLGA 
nanoparticles to actively target cancer cells. Their results indicated good cancer cell recognition of 
surface-modified nanoparticles than that of noncoated nanoparticles.  
The Medical Applications of Nanoparticles 
Nanoparticles have been widely applied in therapeutics, diagnostics and imaging in medical and 
pharmaceutical fields. In therapeutics, surface-modified or multifunctional nanoparticles have been 
used to delivery various therapeutic drugs such as cancer therapeutics, vaccines, nucleic acids. They 
increase the effective drug concentration at desired diseased sites and decreased undesirable side effects 
of the current therapeutic. For example, the most frequently used chemotherapeutic antitumor drugs 
such as carboplatin, paclitaxel, doxorubicin and etoposide, etc., have been successfully loaded onto 
NPs and dramatically decrease their side effect to tumor-suffered patients.  
Molecular diagnostics and imaging emerged with the combination of nanomaterials, 
noanotechnology and modern advanced analysis instrumentation. The emergence of molecular 
diagnostics not only tremendously improves the medical diagnostic lever, provides more solid 
evidences for doctors, and also accelerates the development of cell and molecular biology. Nanoparticle 
is a major member of molecular diagnostics agents, i.e., gold (Au) NPs [20] and quantum dots (QDs) 
[21]. They are capable to detect cancer markers in blood assays or cancer tissue biopsies at pg/mL scale. 
On the other hand, the conjugation of various fluorescent molecules on nanparticles could be as 
imaging agents to track and image nanoparticles from systemic to subcellular lever. 
The Classification of Nanoparticles in Nanomedicine 
As discussed above, many types of nanoparticles have varying formulations can be formulated from 
diverse materials with unique architectures to treat a particular disease. Polymeric nanoparticles are the 
most frequently used nanoscaled DDS. Based on various chemical structures, a number of synthetic 
and natural polymers such as polylactide (PLA) [22], (PCL) [23] poly D, L-lactide co-glycolide (PLGA) 
[24] chitosan [25], and alginate [26] have been formulated by varying processes into 
nanoparticles/nanosphrees or nanocapsules. These Biodegradable materials used for the formulation of 
nanoparticles allow sustained drug release within the target site over a period of days or even weeks. In 
addition, the polymeric nanoparticles surface could be conveniently conjugated with various functional 
groups and other ligands, thus it makes targeting specific diseased sites possible.  
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Solid lipid nanoparticles (SLN) which are formulated from solid lipids such as triglycerides, 
complex glyceride mixtures and waxes have been used as controlled release DDS since 1990s [27]. 
SLN have been applied for topical, oral, pulmonary, parenteral application routes due to their good 
tolerability and biodegradability [28].  
Recently, ceramic nanoparticles as inorganic particles are more and more used for drug delivery due 
to their ultra fine size (generally below 50nm) and porous structure. They can avoid the uptake by 
reticuloendothelial system (RES) due to their very small size [28]. Further more, they can also 
effectively protect various bioactive molecules from the denaturation caused by changes in the external 
pH and temperature due to their stability on external conditions. The biocompatible materials such as 
silica [29], alumina [30], titania [31], etc. have been formulated into ceramic nanoparticles. In addition, 
the particle surface could be conveniently modified by various targeting moieties to be processed as 
active targeting vehicles [32].  
Magnetic nanoparticles are important nanocarriers in the biomedical and biological field, which is 
mainly contributed to their specific targeting functions. For instance, the antitumor drug loaded 
magnetic nanoparticles could be specifically concentrated at tumor sites by the introduction of external 
an external agent (magnetic fields, light, radiation, etc…) to improve the efficiency of 
chemotherapeutics and decrease undesirable side effects [33]. Magnetic nanoparticles are always used 
in the formulation of magnetic colloids which consist of magnetic nanoparticles and a dispersant such 
as water [34]. Thus, the stability of colloid is very important for magnetic colloid. In order to increase 
the repulsive force between particles to avoid flocculation, synthetic or natural polymers are always 
used to coat the particle surface [35].  
Polymeric micelles are nanoscaled core/shell structures formed by amphiphilic block copolymers. 
Polyethylene glycol (PEG) [36] is always used as the hydrophilic block, meanwhile, poly (propylene 
oxide), poly (L-amino acid)s and poly (ester)s are most frequently used as the hydrophobic blocks [37]. 
The polymeric micelles used for drug delivery have shown the abilities to attenuate toxicities, enhance 
delivery to desired biological sites and improve the therapeutic efficacy of active pharmaceutical 
ingredients. These probably are contributed to their small size and hydrophobic shells which can avoid 
the uptake by RES. 
Dendrimers, also called arborols or cascade molecules, are macromolecules composed of multiple 
perfectly branched monomers that emanate radially from a central core [38]. On architecture, 
dendrimers consist of three major domains including a multivalent surface which contains a large 
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number of reactive sites, the interior shells surrounding the core and the core which the dendrons are 
attached on. Dendrimers could serve as potential targeting nanocarriers due to the presence of a large 
number of surface functional groups. In addition, the solubility of dendrimers could be modulated by 
varying end groups on surface. On the other hand, the core could be also tailored to encapsulate 
aqueous soluble or hydrophobic drugs to achieve sustained drug release. Many polymers have been 
used to prepare dendrimers such as polyamidoamines (PAMAMs), polyamines, polyamides 
(polypeptides), poly (aryl ethers), polyesters, carbohydrates and DNA. Among them, the commercially 
available polyamidoamine (PAMAM; StarburstTM) dendrimers [39] and poly (propylenemine) (also 
called PPI, DAB; Astramol®) dendrimers have been most widely studied for biomedical use. 
1.2 The Application of Chitosan on Biomedical Engineering 
1.2.1 Structure and Physicochemical Properties of Chitosan 
Chitosan is a linear copolymer composed of Nacetyl-d-glucosamine and d-glucosamine units 
available in different proposion depending upon the degree of deacetylation (Fig. 1). The history of 
chitosan dates back to the 19th century, when Rouget discussed the deacetylated form of chitin in 1859 
[40]. It is obtained by the deacetylation of chitin which is an abundant natural source widely found in 
the shells in insects, crustaceans and several fungi. Chitin is insoluble in aqueous solution or organic 
solvents. However, chitosan can be dissolved in weekly acetic aqueous solution due to the protonation 
of amino groups. After refinement, chitosan has a rigid crystalline structure through inter- and 
intra-molecular hydrogen bonding. 
The primary amino groups offer chitosan some special properties such as water-solubility, 
hemocompatibility, and cationic groups which could react with a big number of anions or other 
negatively charged molecules. And also based on the cationic property, chitosan-based or coated 
formulations could adhere to negatively charged biosurfaces or membranes. The hydroxyl groups could 
serve as the modification sites by other molecules or polymers, by which a verity of chitosan 
derivatives have been developed [41]. 
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Fig. 1.1 Chemical Chemical Structure of Chitin and Chitosan. 
1.2.2 Biodegradability, Biological Properties and Toxicity of Chitosan 
  Chitosan could be degraded by acid catalyzed degradation, for instance, in stomach. In addition, 
enzymes such as lysozyme, bacterial enzymes in the colon [42] and some chitosanases [43] can 
degrade chitosan by hydrolyzing the glucosamine–glucosamine, glucosamine–Nacetyl-glucosamine 
and N-acetyl-glucosamine–N-acetylglucosamine linkages in vertebrates [44]. Some studies revealed 
that the biodegradability of chitosan is deacetylation degree-dependent and the higher the deacetylation 
degree, the less the degradation is [45, 46].  
Chitosan has some favorable biological properties including mucoadhesion, enhanced mucosal 
epithelial permeability, and immune adjuvant effects [47]. The mucoadhesive property of chitosan 
enhances or prolongs drug absorption and thus permits maximal drug availability to the mucosal 
epithelium. Smith et al. proposed that chitosan could enhance the epithelial permeability by transiently 
opening the cell tight junction [48]. While, chitosan as an immune adjuvant have been found to 
enhance local and systemic immune responses to influenza, tetanus toxoid, diphtheria and pertussis 
vaccines when delivered intranasally [49-52]. In addition, chitosan was found to be toxic for some 
bacteria [53], therefore, it can serve as an antibiotic material. 
1.2.3 The Biomedical Applications of Chitosan 
Chitosan has been extensively used in tissue engineering including bone, cartilage, liver, and nerve 
tissue engineering [54]. Tissue engineering is aimed to develop biocompatible substitutes to restore, 
maintain, or improve biofunction of dysfunctional human tissues or organs. Since chitosan is 
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biodegradable and nontoxic, it has been formulated into a verity of forms such as film, powder, gels. In 
addition, various modification of chitosan could be made to improve the cell seeding. In bone tissue 
engineering, chitosan has been shown to promote cell growth and mineral rich matrix deposition [55]. 
In cartilage tissue engineering, glycosamine glycans (GAGs) plays a pivotal role in modulating 
chondrocytes morphology, differentiation, and function [56]. While, chitosan is chosen as scaffold 
material in cartilage tissue engineering due to its structural similarity to GAGs [57]. In live tissue 
engineering, the bioartificial liver needs to provide an extracellular cell matrix (ECM) like surrounding 
for the seeded primary hepatocytes or liver stem cells. Also for the similarity with GAGs which are 
components of ECM, chitosan frequently serves as the scaffold material for hepatocytes culture [58, 
59]. In nerve engineering, artificial tubes are the effective means to repair injured nerves by bridging of 
nerve stumps. Chitosan is suitable for nerve regeneration due to its biocompatible and biodegradable 
properties. In addition, bioadhesive chitosan could favour the adhesion of nerve cells to the tube lumen 
[60].  
Chtiosan has been widely applied in drug delivery in a verity of forms such as film or membrane 
[61], hydrogel system [62] and particulate system [63]. A big number of drugs and biomolecules could 
be delivered by chitosan-based drug delivery systems, i.e., proteins/peptides, genes, antibiotics and 
chemotherapeutics. With the favorable biodegradable and nontoxic properties, chitosan could be 
fabricated to hydrogel through gel gelation without the use of cross-linking moieties through 
electrostatic, hydrophobic, and hydrogen bonding forces between polymer chains or covalently 
cross-linking available –NH2 and –OH groups on chitosan by various cross-linkers such as small 
molecule cross-linkers, polymers or photosensitive agents. For example, genipin, a naturally derived 
cross-linking agent is effective to cross-link chitosan which contains amino groups [64]. The 
chitosan-based particulate systems will be discussed in the following section. 
Besides tissue engineering and drug delivery applications, chitosan also has been used in 
wound-healing formulations. For a wounding-healing formulation, it should protect the wound from 
bacterial infection as well as promote healing process. Chitosa was found to induce wound-healing on 
its wound and produce less scarring due to its antibiotic property [65]. In addition, endothelial cell 
proliferation enhanced growth factors such as fibroblast growth factor-2 (FGF-2) could be enclosed in 
the formulation to accelerate this wound-healing process [66].  
Because of the excellent non-toxic, hygrophilic and cationic properties, chitosan has also been 
frequently used in bioimaging. As discussed before, some metal or magnetic based imaging agents are 
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commonly in a colloid form to avoid agglutination. Chitosan are always used as coating or conjugation 
material to stabilize these imaging agents and decrease their toxicity [67]. Besides as coating material, 
the imaging agents such as super paramagnetic iron oxide [68], gadolinium [69] etc. could be 
encapsulated or entrapped in chitosan particles as well. 
1.3 Chitosan Microparticles 
  Chitosan particles have found a verity of applications in biomedical and pharmaceutical fields in past 
few decades. In this section, beginning with the application of chitosan in biomedical engineering, the 
emphasis is put on chitosan microparticles.  
1.3.1 The Preparation Methods of Chitosan Microparticles 
  Microparticles, also called microspheres were used to extend the life span of active drugs and 
control the drug release. The total dose and release kinetics can be manipulated to achieve desired 
result by varying the copolymer ratio, molecular weight, polymer concentration etc. First, the 
preparation methods of chitosan microparticles are discussed in this section. Fig. 2 represents these 
methods [70].  
 
Fig. 1.2 Methods for the Preparation of Chitosan Microparticles. Adopted from V.R. Sinha et al., 
2004, International Journal of Pharmaceutics. 
Ionotropic Gelation 
The polycationic chitosan in weak acetic solution could be gelated by a verity of counterions 
including low molecular weight anions such as diphosphoric acid, tripolyphosphate, etc., hydrophobic 
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counterions such as alginate, κ-carragenan, poly-1-hydroxy-1-sulphonate-propene-2, 
polyaldehydro-carbonic acid, high molecular weight ions such as octyl sulphate, lauryl sulphate, 
hexadecyl sulphate, and cetylstearyl sulphate [71]. Chitosan solution was extruded dropwise through a 
needle into various counterions aqueous solutions under magnetic stirring. 
Emulsification and Ionotropic Gelation 
In this method, a water-in-oil (w/o) emulsion is obtained firstly by emulsifying chitosan aqueous 
solution in an oil phase containing proper surfactant. Thereafter, various counterions solutions are 
added to solidify chitosan emulsion droplets [72]. The particle size could be manipulated by controlling 
the size of chitosan emulsion droplets, which can be realized by using different emulsification means, 
i.e. magnetic stirring, homogenization or sonication. In addition, the quantity and concentration of 
cross-linking agents influence the final particle size as well. This method may have disadvantages of 
the use of organic solvent and harsh mechanical shear force. 
Coacervation/Precipitation 
  Since chitosan is insoluble in alkaline medium, chitosan microparticles can form when chitosan 
solution comes in contact with alkaline solution [73]. This method avoids the use of unfavorable 
organic solvent used in emulsification method. However, it still has the drawback of the use of strong 
base which could compromise the activity of biomolecules. Besides, chitosan microparticles could also 
be obtained by the addition of a precipitant, i.e., sulfate to precipitate chitosan out from solution [74]. 
This method avoids the use of toxic organic solvents and glutaraldehyde which is used as a covalent 
cross-linked. But, the obtained particles by this method may have a weak mechanical property and 
irregular morphology.  
Spray-drying 
Spray-drying method is commonly used to produce powders, granules from the mixture of drug and 
excipient. The microparticles are obtained by the atomization of drug-excipient mixture in a stream of 
hot air or by immediate evaporation of excipient. Several parameters could affect the particle size, for 
instance, the nozzle size, spraying flow rate, atomization pressure, inlet air temperature and extent of 
cross-linking. For preparing chitosan microparticles, the drug could be dissolved or dispersed in 
chitosan solution followed by the addition of a proper cross-linking agent. Afterwards, this solution or 
dispersion is atomized in a stream of hot air which leads to instantaneous formation of free flowing 
particles [75]. 
Sieving Method 
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  Agnihotri et al. proposed a novel sieving method to produce chitosan microparticles [76]. As 
shown in Fig. 3, a 4% (m/v) chitosan pre-crosslinked hydrogel was pushed to pass through a sieve with 
micropores under certain pressure to form chitosan microparticles. Using this method, chitosan 
microparticles could be simply produced in a large scale. Further more, the obtained particles could 
have a very narrow size distribution due to the homogeneous pore size of the sieve. 
 
Fig. 1.3 Schematic Representation of Preparation of Chitosan Particulate Systems by Seiving 
Method. Adopted from Agnihotri SA, Aminabhavi TM, 2004, J Control Release. 
 
Microfluid Chip Technology 
  The conventional methods for preparing chitosan microparticles such as ionic gelation, 
emulsification, coaervation and spry drying etc. generally have disadvantages such as unstable yield, 
tedious procedures and wide size distribution. In order to realize a reproducible and practical method 
for the pharmaceutical industry, microfluidic chip technique is introduced to the field. Microfluidic chip 
(containing cross-junction microchannel) emulsification is a relatively new technique for preparing 
water-in-oil (w/o) and oil-in-water (o/w) emulsions in these years. Yang et al. [77] applied a 
cross-junction microchannel of a microfluidic device coupled with gelation reaction to control the 
performance of uniform TPP-chitosan microspheres (Fig.4). The obtained chitosan microparticles by 
their device had a narrow size distribution (polyindex = 1) which was suitable to provide the optimal 
release rate in the administration of controlled release drugs. Therefore, it was included that 
microfluidic chip is capable of generating relatively uniform micro-droplets and has the advantages of 
actively controlling the droplet diameter, and having a simple and low cost process, with a high 
throughput. 
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Fig. 1.4 Using a Cross-flow Microfluidic Chip and External Crosslinking Reaction for 
Monodisperse TPP-chitosan Microparticles. (a) Schematic presentation of the formation of chitosan 
emulsion in a cross-junction microchannel. Based on microfluidics to exert control over the focusing 
force, a large set of uniform self-assembling spheres can be obtained. The emulsions are gelled upon 
contact with 10% (w/v) P3O105−, and the chitosan molecules entrapped in the micro container (emulsion) 
are transformed into TPP-chitosan particles in the reservoir. (b) Experimental setup of a microfluidic 
chip system for the generation of TPP-chitosan microparticles. Schematic presentation and photo image 
of microfluidic chip: (c) the chip in expanded view and (d) the photo image of the chip: 1, oil inlet; 2, 
sample inlet; 3, cross-junction channel; 4, broadened channel; 5, observation chamber (1200μm in 
width channel); 6, outlets; 7, screw holes for bonding. Adopted from Yang et al., 2007, Sensors and 
Actuators B. 
1.3.2 The Application of Chitosan Microparticles 
  As a DDS, chitosan microparticles find a number of applications in pharmaceutics. This is mostly 
contributed to the biodegradable, nontoxic and bioadhesive properties of chitosan. The major 
applications of chitosan microparticles are discussed below, generally from the administration route 
point of view.  
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Oral Drug Delivery 
Oral drug delivery has the advantages of ease of administration and improved patient convenience 
and compliance. Chitosan microparticles have been developed to deliver various drugs via oral route. 
Chitosan has been shown to effectively bind DNA in saline or acetic acid solution and protect DNA 
from nuclease degradation. Ülker Guliyeva et al. [78] reported that plasmid DNA could be 
encapsulated into chitosan microparticles without damage by oral administration. I.M. van der Lubben 
et al. reported an ovalbumin loaded chitosan microparticles prepared by coacervation/precipitation 
method [79] as an oral vaccine. Their results indicated that chitosan microparticles showed suitable in 
vitro and in vivo characteristics for oral vaccination.  
Nasal Drug Delivery 
  Nasal drug delivery offers several benefits such as highly vascular mucous membrane, lower 
enzymatic degradation compared to oral route, and better patient compliance. However, mucocilliary 
clearance and insufficient drug uptake are the major barriers for nasal drug delivery. Chitosan 
microparticles have been studied as vaccine carriers in nasal vaccination. Some investigations 
evidenced that chitosan microparticles could enhance the immune response of encapsulated vaccines by 
improve the vaccine uptake by specialized M cells and Peyer's patches of mucosal associated lymphoid 
tissues (MALTs) [80]. 
Colon and Intestinal Drug Delivery 
Chitosan microparticles could be used for colon- and intestinal-specific drug delivery, because 
chitosan can be degraded by microflora which exist in colon. Lorenzo-Lamosa et al. [81] reported a 
chitosan microcore encapsulated acrylic microspheres which took advantages of the colon-specific 
degradation of chitosan microscore (microparticles, 2~3 μm) and pH dependent property of acrylic 
materials. Mladenovska et al. [82] reported chitosan-Ca-alginate microparticles to specifically deliver 
5-aminosalicylic acid to colon. The non-solubility of chitosan at pH values higher than 6.5 leads to 
slow erosion of chitosan-alginate complex and consequential controlled drug release in the colon where 
the pH value is in the range of 6.5-7.0.  
1.4 Chitosan Nanoparticles 
  Chitosan nanoparticles have been extensively applied to deliver a large range of chemicals and 
biomacromolecules based on the excellent properties of chitosan discussed above. Many methods have 
also developed to prepare chitosan nanoparticles. According to different preparation methods and drug 
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delivery purposes, chitosan nanoparticles found a verity of applications in pharmaceutics.  
1.4.1 The Preparation Methods of Chitosan Nanoparticles 
  Even though some preparation methods of chitosan microparticles can be used to prepare 
nanoparticles, whereas, down to nanoscale size, some parameters like the concentrations of chitosan 
and ionotropic gelation agents and input energy have to be accordingly modified. Here, the most 
frequently preparation methods are presented as follows.  
Emulsification Solvent Diffusion Extraction 
  El-Shabouri et al. reported using emulsification solvent diffusion extraction method to prepare 
chitosan nanoparticles [83]. An oil-in-water emulsion was obtained by adding an organic solvent 
partially miscible into chitosan solution containing a stabilizing agent under magnetic stirring, followed 
by high-speed homogenization. The resulting emulsion was diluted in a large amount of water to 
extract the organic solvent. Nanoparticles were obtained as a result of the diffusion of the organic 
solvent into water. The particle size of obtained particles was between 104-148nm and showed a zeta 
potential of +31.2 mv. The bioavailability and biological effect of the highly lipophilic drug 
(cyclosporin-A) showed a significant increase in comparison to the reference Neoral microemulsion. 
Emulsion-droplet Coalescence 
Tokumitsu et al. [84] firstly reported an emulsion-droplet coalescence technique to prepare chitosan 
nanoparticles. In this method, both chitosan and NaOH solution were emulsified into the same oil phase 
under the conditions to prepare two emulsions. The two emulsions were then mixed and stirred at high 
rotating speed to form chitosan nanoparticles. The hydrophilic drug- gadopentetic acid encapsulated 
chitosan nanoparticles had a diameter of 452 nm and were proved suitable to be intravenously injected.  
Ionotropic Gelation 
Based on ionotropic gelation, chitosan can be ioniclly cross-linked by counterions such as Fe(CN)64−, 
Fe(CN)63−, citrate and sodium tripolyphosphate (TPP) etc. to form hydrogel and microparticles like 
discussed above. When the concentrations of chitosan and these anions decrease to enough low values, 
nanoparticles are able to generate. This method allows the preparation of chitosan nanoparticles in 
aqueous solution and avoids the use of organic solvents and high dispersion energy which may 
compromise the drug activity, therefore, once upon reported, it has drawn extensive attention and has 
been used to encapsulate a number of chemical or biological molecules which are sensitive to the 
preparation conditions. This method was firstly reported by Calvo et al. in 1997 [85]. Following studies 
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revealed that chitosan nanoparticles could form with specific concentrations of chitoan and TPP 
solution and amount ratio between them. When chitosan concentration is too low, the suspension is 
translucent, which means no particles generate. When chitosan concentration is too high, the 
suspension may too instable to form aggregates. When chitosan solution is in a appropriate 
concentration range, the opalescent suspension is obtained in which nanoparticles can be further proved. 
The main drawbacks of the chitosan nannoparticles produced by this method are drug burst release 
effect and low particles yield.  
Complex Coacervation 
  Similar to ionotropic gelation method, complex coacervation method has been used to prepare 
chitosan nanoparticles through the ionic reaction between cationic chitosan and anionic polyanions, 
polymers or biomacromolecules rather than anions adopted by the former. Hu et al. [86] repoted 
chitosan–poly(acrylic acid) nanoparticles which were affected by the ratio between the two 
polyelectrolytes. Chtiosan/Alginate nanoparticles have been developed to deliver bioactive molecules 
such as proteins and nucleic acids [87]. chitosan and nucleic acid molecules can form nanoparticles at 
appropriate ratio to serve as a nonviral gene nanovehicle [88].  
Self-assembling Micelles 
  As discussed above, amphiphilic block copolymers can form micelles. To date, chitosan has been 
modified into numerous hydrophobic chitosan derivatives to prepare into chitosan micelles. For 
example, Kim et al. [89] reported a 5β-cholanic acid modified glycol chitosan to deliver an anticancer 
drug-paclitaxel.  
1.4.2 The application of chitosan nanoparticles 
Oral, Nasal and Pulmonary Drug Delivery 
As discussed in the section of chitosan microparticles, the oral drug delivery has the advantages of 
convenience and good patient compliance. However, the enzymatic digestion and low mucosal 
absorption are the main barriers for some drugs which are sensitive to these harsh conditions. Based on 
the favorable bioadhensive and enhanced permeability properties chitosan, it has been formulated to 
nanoparticles to deliver these drugs. Beside above mentioned advantages of chitosan microparticles, 
chitosan nanoparticles also has its size advantages which can allow them more easily absorbed by 
mucosal epithelium cells. Sarmento et al. reported that [90] alginate/chitosan nanoparticles 
administered orally to diabetic rats were found effective for oral insulin delivery. Zang et al. [91] 
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reported that water-soluble chitosan nanoparticles enhance and prolong the intestinal absorption of 
bovine serum albumin 
  Pulmonary and nasal drug administrations are also frequently used means due to their large 
absorbance surface area. Al-Qadi et al. [92] reported a new dry powder system consisting of 
microencapsulated insulin-loaded chitosan nanoparticles. The mild preparation conditions of chitosan 
nanoparticles protected the insulin bioactivity well, whereas, the final spray dried powder provided an 
adequate aerodynamic property for deposition in deep lungs. The assessment of the plasmatic glucose 
levels following intratracheal administration to rats revealed that the microencapsulated insulin-loaded 
chitosan nanoparticles induced a more pronounced and prolonged hypoglycemic effect compared to the 
controls. 
  Shahnaz et al. [93] et al. reported a thiolated nanoparticle to enhance the bioavailability for the nasal 
application of leuprolide. The inter- and/or intramolecular disulfide formation within the NPs network 
stabilized obtained nanoparticles and achieved a sustained leuprolide release over 6 hours. Ciliary beat 
frequency study demonstrated that thiolated chitosan nanoparticles could be considered as suitable 
additives for nasal drug delivery systems. 
Ocular Drug Delivery 
  The short residence time, drug drainage and frequent instillation are the major drawbacks of the 
conventional drugs for ophthalmic diseases. Chitosan nanoparticles have been used to deliver ocular 
drugs to solve above limitations. De la Fuente et al. [94]. reported a hyaluronic acid-chitosan 
nanoparticles to deliver genes to the cornea and conjunctiva. Both of chitosan and hyaluuronic are the 
polysaccharide with good bioadhisive and permeability enhancement properties, besides, hyaluronic 
acid is known for its implication in several processes, such as the regeneration of corneal and 
conjunctival epithelial cells, through an interaction with the CD44 receptor. Their results indicated that 
hyaluronic acid-chitosan nanoparticles were able to target and further transfer genes to the ocular 
surface. 
Vaccine Delivery 
Nanoparticles often present significant adjuvant effects in parenteral vaccine delivery due to their 
effective uptake by antigen presenting cells. The nanoscaled size allows nanoparticles to be taken up by 
M-cells in mucosa-associated lymphoid tissue (MALT), i.e., gut-associated, nasal-associated and 
bronchus-associated lymphoid tissues, to initiate vigorous immunological responses. Chitosan 
nanoparticles have been used in vaccine delivery due to their bioadhesive, biocompatible, 
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biodegradable and permeation-enhancement properties. They can be effectively uptaken by 
phagocytotic cells inducing strong systemic and mucosal immune responses against antigens. Zheng et 
al. [95] investigated the immune stimulation mechanisms of ovalbumine (a frequently used antigen 
model) loaded chitosan nanoparticles. They suggested that chitosan nanoparticles had a strong potential 
to increase both cellular and humoral immune responses and elicited a balanced Th1/Th2 response, and 
that chitosan nanoparticles may be a safe and efficacious adjuvant candidate suitable for a wide 
spectrum of prophylactic and therapeutic vaccines. 
Gene Delivery 
As a nonviral gene carrier, chitosan nanoparticles are able to reduce the risk of cell toxicity and even 
induce strong immune responses. To date, chitosan nanoparticles have been applied to deliver DNAs, 
and RNAs mainly through the complex coacervation between polycationic chitosan and polyanionic 
nucleic acid molecules. Among them, one hot scope in life biology since the last decade of 20th century 
is the gene silencing technique which is induced by long double-stranded RNAs (dsRNA), small 
interfering RNAs (siRNA) or microRNAs (miRNA). One limitation of the delivery of siRNAs into 
cells is rapid degradation and poor cell absorption of these small molecules. Katas et al. [96] reported a 
100% protecting of siRNAs from nuclease degradation by chitosan nanoparticles. However, generally 
gene transfection efficiency of chitosan nanoparticles is lower than that of viral gene carriers. 
Improving transfection efficiency is a challenge for using chitosan nanoparticles as a gene carrier. 
Mansouri et al. [97] reported a folic acid modified chitosan nanoparticles to improve gene tranfection 
efficiency. Their results revealed that the obtained folic acid-modified chitosan nanoparticles showed a 
low cell toxicity and were able to condense DNA effectively with ideal size and zeta potential. 
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Chapter 2 Chitosan Nanoparticles for the Controlled Release of 
Proteins 
2.1 Aim of the Study 
  In this section, protein-incorporated CSNPs were prepared for the preservation, delivery and 
controlled release of protein molecules. Since quite a few factors could influence the features of CSNPs 
as a protein nanocarrier, in order to achieve ideal particulate characters, protein payload and release 
profile, the primary influent factors such as CS concentration, CS/TPP mass ratio, BSA concentration, 
pH value are investigated. Some extra characterizations of CSNPs are also performed to have a glance 
of the formation mechanism of CSNPs. In the end, as a perspective, some preliminary trials are 
preformed on the purpose to overcome the burst release effect of CSNPs. 
2.2 Materials and Methods 
2.2.1 Materials 
Low molecular weight chitosan supplied by Sigma (448869) with a deacetylation degree (DD) of 
75-85% and viscosity of 20-300 cP (1% in 1% acetic acid) was used in section 2.3.1, 2.3.2, 2.3.3, and 
2.3.6. PROTASAN UP CL 113 (soluble chitosan chloride) supplied by NovaMatrix/FMC Corporation 
with a DD of 75-90% was used in section 2.3.4 and 2.3.5. Albumin from bovine serum (BSA) with 
molecular weight ~66 KDa was supplied by Sigma. VEGF was kindly provided by Prof. Giacca 
(International Centre for Genetic Engineering and Biotechnology, ICGEB). Sodium tripolyphosphate 
(TPP), phosphoric acid, brilliant blue acetic acid, ethanol, phosphate buffered saline (PBS, pH 7.4, 
tablet) were supplied by Sigma. 
2.2.2 Instruments 
Magnetic stirrer (RCT-Basic) was purchased from IKA Corporation. Centrifuge (Mikro 220) was 
purchased from Hettich Corporation. Lyophilizer (CoolSafe) was purchased from Scanvac Corporation. 
Zetasizer (Nano S90) for particle size measurement was purchased from Malvern Corporation. Fourier 
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transformation infrared (FT-IR) spectrometer (Frontier) was purchased from Perkin Elmer Corporation. 
Scanning electron microscope (SEM, 1450VP) for morphological observation of particles is the 
product of LEO Corporation. Ultraviolet/Visible spectrophotometer for the measurement of protein 
concentration is the product of Perkin Elmer Corporation. Differential scanning calorimeter (DSC-Q20) 
is the product of TA Corporation. Incubating shaker (KS 4000ic -3510100) was purchased from IKA 
Corporation. 
2.2.3 Methods 
Preparation of Chitosan Nanoparticles 
  Here, CSNPs were prepared according to an ionic gelation method adopted by Calvo et. al. [98] to 
prepare CSNPs. For section 2.3.1, 2.3.2, 2.3.3, 2.3.6., low molecular weight chitosan was dissolved in 
Milli-Q water containing 0.4% (m/v) acetic acid to a concentration of 4 mg/ml as stock solution. TPP 
was dissolved in Milli-Q water to a concentration of 2.5 mg/ml as stock solution. Both of the two stock 
solutions were tuned to pH 5. Two milliliters of TPP solution was added to 5 ml chitosan solution under 
continuous stirring at 500 rpm for 30 minutes at room temperature. The reactions were performed in a 
10 ml-beaker. CSNPs spontaneously formed via the electrostatic attraction between positively charged 
primary amino groups on chitosan chains and reversely charged polyanions. The resulting opalescent 
suspensions were determined as CSNPs. The concentrations of chitosan, TPP, BSA were adopted 
according to Table 1. Every sample was prepared in triplicate. The resulting nanoparticles suspensions 
were stored at 4 C for further analysis. Considering that many factors except for above mentioned ones 
could influence the formation of colloidal CSNPs, for instance, temperature, stirring rate, the same 
beaker, magnetic stirrer, and stirrer bar were always used for all samples. 
In the above study using low molecular weight chitosan as the material for the preparation of CSNPs, 
impurities remaining in material which could influence light absorbance of sample were found in 
protein concentration determination step. In order to investigate more accurately the influence of pH 
value on the formation of CSNPs, a more purified soluble chitosan chloride was chose in section 2.3.4 
and 2.3.5. The volume of reaction system was also increased to obtain a increased amount of 
nanoparticles. In this case, 28 ml TPP solution was mixed with 70 ml chitosan solution in a 100 
ml-beaker under continuous stirring at 600 rpm.  
For the preparation of VEGF-incorporated CSNPs, LMWCS was used as preparation material and 
the preparation parameters were as follow: 2 mg/ml CS solution (pH 5), 1.67 mg/ml TPP solution (pH 
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5), CS/TPP volume ratio: 5/2 (mass ratio: 3/1), amount of VEGF: 46μl 5 ng/μl, total reaction volume: 
23 ml. 
Table 2.1 The Concentrations of Chitosan, TPP, and BSA in the Preparation of CSNPs in section 
2.3.1, 2.3.2, 2.3.3, and 2.3.6. 
Sample 
Chitosan 
(mg/ml) 
TPP 
(mg/ml) 
CS/TPP Mass 
ratio 
BSA 
(mg/ml) 
1  2 1 5 0 
2  2.5 1.25 5 0 
3  3 1.5 5 0 
4  3.5 1.75 5 0 
5  4 2 5 0 
6  2 1 5 1.5 
7  2.5 1.25 5 1.5 
8  3 1.5 5 1.5 
9  3.5 1.75 5 1.5 
10  4 2 5 1.5 
11  3  2.5 3 0 
12  3  1.875 4 0 
13  3  1.5 5 0 
14  3  1.25 6 0 
15  3  1.071 7 0 
16  3  2.5 3 1.5 
17  3  1.875 4 1.5 
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18  3  1.5 5 1.5 
19  3  1.25 6 1.5 
20  3  1.071 7 1.5 
21  3  1.5 5 0.5 
22  3  1.5 5 1 
23  3  1.5 5 1.5 
24  3  1.5 5 2 
25  3  1.5 5 2.5 
 
Yield Analysis of CSNPs 
  Eppendorf (EP) tubes being of the size of 1.5 ml were weighed on electronic balance. One milliliter 
CSNPs suspension of each sample was centrifuged at 15,000 rpm for 20 min. at room temperature. 
After supernatant was completely removed, EP tubes bearing particles pellets underwent vacuum 
drying over night at room temperature. Afterword, tubes were weighed again. All the samples were 
repeated in triplicate. The yield of CSNPs/BSA-CSNPs were determined according to the equation as 
follows: 
%100(%) ×=
MaterialsUsedofWeightTotal
ParticlesofWeightYield  
Particle Size Measurement 
  Particle size measurement of CSNPs was performed by Zetasizer S90 based on dynamic light 
scattering (DLS) technique. One milliliter suspension of each sample was filled in a disposable 
polystyrene vial to be analyzed. Particle size values were given in the term of Z-average size (by 
intensity) along with a polydispersity index (PDI). 
Determination of Encapsulation Efficiency of CSNPs 
  One milliliter particles suspension was centrifuged at 15,000 rpm for 20 min. at room temperature. 
100 ml supernatant was used for the measurement of protein concentration using Bradford protein 
assay [99]. Briefly, spectrophotometer was warmed up before use. A set of BSA standards (0.1, 0.3, 0.6, 
0.9, 1.2 mg/ml) were prepared to plot a standard curve (see Fig.2.1). 5 ml dye regent (dissolve 100 mg 
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Coomassie Brilliant Blue G-250 in 50 ml 95% ethanol, add 100 ml 85% (w/v) phosphoric acid, dilute 
to 1 liter when the dye has completely dissolved) was added to 100 μl sample solution. The mixture 
was agitated followed by incubation for 5 min. The absorbance of sample was measured at the 
wavelength 595nm by spectrophotometer. The encapsulation efficiency (EE) and Loading Capacity 
(LC) of CSNPs was determined according to the equation as follows 
%100
Pr
tanPrPr(%) ×−=
AmountoteinlTheoretica
tSupernainAmountoteinAmountoteinlTheoreticaEE  
%100(%) ×−−= BSALoadedofWeightCSNPsBSAofWeight
BSALoadedofWeightLC  
Each CSNPs sample was used as the control of its BSA-CSNPs counterpart. 
BSA Standard Curve
y = 0.8559x + 0.0856
R2 = 0.9959
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Fig. 2.1 BSA Standard Curve by Bradford Protein Assay. 
 
Scanning Electron Microscpy (SEM) Analysis 
  CSNPs were analyzed using SEM (LEO 1450VP). One drop of freshly prepared particles 
suspension was deposited on sample stub covered with carbon tab. The sample was air-dried followed 
by covered with gold. Low voltage was set to observe CSNPs since at high voltage e.g. usually used 20 
KV, CSNPs are highly heated by strong electron stream then deform or even decompose rapidly. In our 
study, 10 KV is found harmless to CSNPs. 
Transmission Electron Microscopy (TEM) Analysis 
Morphological characteristics of the nanoparticles were examined using a high resolution 
Transmission Electron Microscope (TEM) machine. One-drop sample was placed on a carbon coated 
film 300 mesh copper grid, allowing sitting for 10 min until air-dried. The sample was stained with 1M 
uranyl acetate solution for 1.5 min at 7 °C and any excess uranyl acetate was removed with filter paper 
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before observation on the TEM machine. 
Fourier Transformation Infrared (FTIR) Spectrometry Analysis 
  FTIR analysis was performed using a Frontier PerkinElmer FT-IR spectrophotometer with 
universal ATR module (Diamond/KRS-5 crystal). The instrument was operated with resolution of 4 
cm−1 and 32 scans with frequency range of 400-4000cm−1. 
Differential Scanning Calorimetry (DSC) Analysis 
DSC analysis was performed using a TA DSC-Q20 instrument. Each freeze-dried sample (5-10 mg) 
is run at a scanning rate of 20 °C/min under nitrogen atmosphere. The temperature for the scan ranged 
from 20 to 280 °C. 
In vitro Release of BSA-CSNPs 
  According to the yield of BSA-CSNPs, 2 mg BSA-CSNPs was collected in a 1.5 ml-size EP tube by 
centrifugation. The supernatant was completely removed away followed by resuspension in 1 ml PBS 
(pH 7.4). The suspension was put in an incubating shaker under continuous shaking at 37°C. At the 
time interval of 1, 3, 6, 24 hours, each sample was centrifuged and 200 μl supernatant was collected 
followed by refilled with 200 μl fresh PBS and resuspended. The concentration of released BSA was 
determined by Bradford protein assay. All samples are performed in triplicate. 
  For the in vitro release of VEGF, an enzyme-linked immuno sorbent assay (ELISA) kit was used to 
measure its concentration at the time interval of 1, 3, 6 and 24 hours and 3, 5, 7, 10, 15, 20 and 30 days 
in Dulbecco's modified eagle medium (DMEM) culture media. 
2.3 Results and Discussion 
2.3.1 The Effect of Chitosan Concentration on the Particle Size and BSA Encapsulation 
Efficiency of CSNPs 
  When other preparation parameters were fixed, the effect of CS concentration on the features of 
CSNPs was investigated. In this section, these fixed parameters are: CS/TPP mass ratio (5/1), BSA 
concentration (1.5 mg/ml). Five CS concentrations were chosen: 2, 2.5, 3, 3.5 and 4 mg/ml. As shown 
in Figure 2.1 A, the yield of CSNPs at all CS concentrations is higher that that of BSA-CSNPs, which 
probably results from the competitive reaction with chitosan between BSA molecules and TPP ions.   
Considering the big standard deviation, no remarkable influence of CS concentration on the yield of 
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CSNPs/BSA/CSNPs could be found. As the increase of CS concentration, particle size of 
CSNPs/BSA-CSNPs increases. Meanwhile, the particles polydispersity also increases, which means the 
formation of big particles or the appearance of aggregates. According to the size distribution diagrams 
(see appendix 1), both above mentioned issues are involved. Increasing CS concentration, increases the 
size of the particles and aggregates begin to appear. Besides, more small particles form as well during 
this process. All of these issues induce a wider size distribution at high CS concentration. The BSA 
encapsulation efficiency (EE) increases from 37% to 45% with the increase of CS concentration from 
2.5 to 4 mg/ml. It’s reasonable that more material and bigger particles could encapsulate more drug. 
However, Q. Gan et al. reported contrary result [100]. Besides, it is worth to notice that there is a drop 
of EE from the first and the second CS concentration which also shows in the case of particles yield. It 
applies that CSNPs prepared at the CS concentration below or above 2.5 mg/ml may show different EE 
trends, since besides of CS concentration, other factors could affect EE of particles, e.g. protein 
concentration and CS/TPP mass ratio. In other words, under our preparation conditions (CS/TPP mass 
ratio: 5/1, BSA concentration: 1.5 mg/ml, total reaction volume: 7 ml, CS/TPP volume ratio: 5/2), we 
found particles EE follows this trend. 
 
Fig. 2.2 The Effect of Chitosan Concentration on the A-Yield, B-Particle Size, C-Particle Size 
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Distribution and D-BSA Encapsulation Efficiency of CSNPs/BSA-CSNPs. 
2.3.2 The Effect of CS/TPP Mass Ratio on the Particle Size and BSA Encapsulation 
Efficiency of CSNPs 
  In this section, 5 mass ratio values (3, 4, 5, 6, and 7) of CS/TPP were chosen to study its effect on the 
features of CSNPs. The other parameters were fixed at CS concentration: 3 mg/ml, BSA concentration 
1.5 mg/ml. Weight analysis result shows that particles yield keeps going down as CS/TPP mass ratio 
increases. Particle size shows the contrary tendency with respect of particles yield. That is to say when 
the obtained CSNPs are becoming larger, less chitosan is gelated by TPP. As CS/TPP mass ratio rises, 
the size distribution also becomes wider. The incorporation of BSA affects the formation of CSNPs (see 
Fig. 2.2B and C). It is interesting to notice that when CS/TPP mass ratio comes from 3 to 4 a relative 
significant increase of particle size is observed. This happens to CSNPs and BSA-CSNPs, but when 
CS/TPP mass ratio continue to increase, particle size of BSA-incorporated CSNPs no longer increases 
significantly. The incorporation of BSA hinders the rise of polydispersity index compared to blank 
CSNPs. This observation implies that BSA hinders the gelation induced by TPP and when the amount 
of TPP is low enough, for instance when CS/TPP mass ratio rises to 4, the presence of BSA starts to 
play a dominant role. However, it is hard to demonstrate how BSA molecules interfere with the gelation 
process between chitosan and TPP. The EE of BSA-CSNPs decreases with the increasing CS/TPP mass 
ratio. One explanation is that high TPP mass at fixed chitosan concentration may cause a rise in 
solution pH value, with a consequential effect on increased overall negative surface charge carried by 
the protein molecules, which enhanced electrostatic interactions between chitosan and BSA molecules 
[101]. In the view of gelation density, higher TPP concentration results in more compact particlulate 
matrix. Consequently more protein molecules are entrapped. 
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Fig. 2.3 The Effect of CS/TPP Mass Ratio on the A-Yield, B-Particle Size, C-Particle Size 
Distribution and D-BSA Encapsulation Efficiency of CSNPs/BSA-CSNPs. 
2.3.3 The Effect of BSA Concentration on the Particle Size and BSA Encapsulation 
Efficiency of CSNPs 
  As discussed in last section, there is no clear mechanism by which protein molecules interfere the 
gelation process of CSNPs. In this section, a series of BSA concentration: 0.5, 1, 1.5, 2 and 2.5 mg/ml 
were set to study its effect on the features of CSNPs. As shown in Fig. 2.4A, BSA concentration shows 
no remarkable influence on the particles yield. It also shows weak influence on particle size of CSNPs 
(see Figure 2.4B and C). Figure 2.4D shows EE of CSNPs drops quickly from 55% to 38% with 
respect to BSA concentration 0.5 to 1.5 mg/ml. In the BSA concentration range of 1.5~2.5 mg/ml, 
particles EE shows a slight increase. Considering that the measuring range of Bradford protein assay is 
0.1~1.4 mg/ml. From the last section we learn that at the constant CS concentration, smaller particles 
gelated by TPP with higher concentration show higher EE. This fits in the case what EE shows in the 
BSA concentration range 0.5~1.5 mg/ml.  
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Fig. 2.4 The Effect of CS/TPP Mass Ratio on the A)Yield, B)Particle Size, C)Particle Size 
Distribution and D)BSA Encapsulation Efficiency of CSNPs/BSA-CSNPs. 
2.3.4 The Effect of pH on the Formation and Encapsulation Efficiency of Chitosan 
Nanoparticles as Protein Nanocarrier 
Chitosan is a natural polysaccharide composed of randomly distributed β (1 → 4)-linked 
glucosamine and N-acetylglucosamine units. Chitosan has found many applications in medical and 
pharmacological field in the forms of films, tablets, membranes, microparticles and nanoparticles due 
to its excellent biocompatible, biodegradable, mucoadhesive, non-toxic, antimicrobial, antiviral 
immunoadjuvant properties [102]. Chitosan is soluble in weakly acetic medium due to the protonation 
of primary amino groups on its chains. This makes chitosan to be a rare, cationic, natural polymer. 
Thanks to this, a variety of anions and negatively charged molecules could form complex or particles 
with chitosan and one of them is TPP. Since Calvo et al. firstly used TPP-cross-linked chitosan 
nanoparticles to deliver protein molecules in 1997 [98], a big number of researches have been 
conducted using CSNPs to deliver various drugs and bioactive molecules. Meanwhile, chitosan is 
always used as coating material to exert its hydrophilic, cationic, mucoadhesive properties [103-105]. 
Not to mention that numerous chtiosan derivatives which are modified up to various purposes have 
been applied to prepare CSNPs [106-108]. In short, the mild and convenient preparation conditions 
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make CSNPs very suitable to be a nanocarrier for bioactive molecules. Further more, excellent 
properties of chitosan such as cationic electric state, bioadhension facilitate the application of CSNPs in 
gene therapy and ocular, oral, pulmonary, gastrointestinal drug administration [102]. 
Even through several methods have been used to prepare CSNPs, i.e. ionic gelation, complex 
coacervation, microemulsion, emulsion-droplet coalescence, ionic gelation especially with TPP as 
cross-linker has been used most frequently so far. By this method, CSNPs are obtained via the 
electrostatic reaction between oppositely charged amino groups of chitosan and tripolyphosphoric ions 
from TPP. Some researchers have investigated the preparation parameters which influence the 
properties of CSNPs, i.e. chitosan molecular weight, concentration, mass ratio of chitosan to TPP, 
protein concentration, stirring rate, temperature and pH value. Among them, the molecular weight 
distribution of chitosan, mass ratio of chitosan to TPP and pH value are the major factors. With a low 
molecular weight chitosan solution filtered by a syringe filter, Fan and colleagues [109] obtained very 
monodispersed CSNPs (polidispersity index, PDI well below 0.05). Calvo and colleagues [98] revealed 
that CSNPs only generated in specific concentration range of chitosan and TPP at appropriate mass 
ratio. While, as respect to the effect of pH value, most studies were conducted on the influence of 
chitosan solution pH. Fan et al. [109] reported the critical mass ratio of chitosan to TPP for the 
formation of an opalescent suspension decreased with the pH decreasing and well monodispersed 
CSNPs only obtained in the pH range of 4.5-5.2. Gan et al. [110] reported a smallest particle size at pH 
5.5 and the beginning of particles aggregation at pH 6.0, but the effect of chitosan solution pH on 
particle size did not follow any specific trends.  
Since pH value has a significant influence on the size and electrical state of CSNPs. Whereas, 
particle size and zeta potential of CSNPs significantly affect the protein encapsulation and release. In 
this study, we further studied the effect of pH value on the formation and properties of CSNPs through 
strictly controlling the pH value of TPP solution. We characterize the CSNPs prepared under various 
pH conditions and attempt to understand the formation and protein encapsulation mechanisms of 
CSNPs better, eventually provid suggestions for avoiding ununiformity and initial burst release 
problems of CSNPs. 
The Effect of pH on the Particle Size and Polydispersity of Chitosan Nanoparticles 
The particle size of CSNPs could be affected by many factors such as chitosan molecular weight, 
deacetylation degree, concentration, TPP concentration, the mass ratio of chtosan to TPP, pH value, 
stirring rate and ambient temperature. In order to investigate the effect of pH on particle size of CSNPs, 
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the other parameters except for solution pH are fixed. Further more, the solution pH of chitosan and 
TPP was adjusted to the same value to reduce the alteration of resulting particles suspension pH.  
In this study, a soluble chitosan salt chitosan hydrochloride (CSCL) was directly dissolved in 
deionized water to get 2 mg/ml solution. The pH of this initial CSCL solution was measured at pH 4.2. 
Two pH values of which one was below 4.2 (3.0) and one above (5.5) along with the initial 4.2 were set 
to prepare CSNPs. As shown in Table 2.2, particle size of CSNPs drops down remarkably as pH 
decreases from 5.5 to 3. At pH 5.5, aggregation happens when too much ionic cross-linking agent TPP 
is present (mass ratio of CS to TPP=3:1). It is worth noting that particle size drops down much more 
from pH 5.5 to 4.2 than that from pH 4.2 to 3. It is known that chitosan is a week polyelectrolyte with a 
pKa around 6.5 and insoluble at neutral and alkaline pH values. In an acetic medium, the primary amino 
groups on chitosan polymer chains are protonated by hydrogen ions to confer to chitosan molecules a 
high charge density [112]. In this study, at the initial pH value (4.2), chitosan polymer chains extended 
well once upon CSCL was completely dissolved in water. When CSCL solution pH value was tuned to 
5.5, partial NH3+ ions were deprontonized which led to the folding of chitosan chains [113]. Thus, 
fewer NH3+ ions were exposed, consequently fewer tripolyphosphric ions were involved in 
cross-linking chitosan, which resulted in a sparsely cross-linked chitosan polymer matrix and 
eventually a bigger particle size. On the other hand, when CSCL solution pH was tuned to 3 from initial 
4.2, the amino groups on chitosan were further protonized which made the electric repulsion between 
chitosan molecules increase. Under this condition, more energy is needed to overcome the electrostatic 
repulsion between chitosan chains and form ionic linkages with TPP ions which resulted in the 
formation of CSNPs with small size. In addition, in the chitosan molecular conformation of view, more 
extended polymer chains at the lower pH value are prone to form more compact particles with small 
size. 
Table 2.2 The Effect of pH on Particle size of Chitosan Nanoparticles. 
Mass Ratio of CS/TPP Particle Size (nm) 
3 4 5 
5.5 ▼ 453.9±17 392.7±5 
4.2 166.9±1.9 155.9±1.5 157.9±1.7 pH 
3.0 127.1±3.2 119.8±2.6 108.8±0.6 
 
▼: Aggregation 
  In comparison with pH value, the mass ratio of chitosan to TPP has less predominant effect on the 
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particle size of CSNPs in this study, which also can be seen from Table 2.2. However, mass ratio of 
chitosan to TPP could contribute to affect the size distribution along with pH. As shown in Fig. 2.5, at 
low mass ratio of chitosan to TPP 3:1, namely more TPP, particle size distribution became wider from 
pH 3 to pH 4.2. Aggregation even happened when CSNPs were prepared at pH 5.5. At pH 4.2, 
polydispersity index (PDI) increased from 0.27±0.02 to 0.42±0.03. As shown in inset A (size 
distribution of CSNPs obtained at pH 4.2) and B (pH 5.5) in Fig. 2.5, at the same mass ratio of chitosan 
to TPP 4:1, it is prone to generate particles with big size at high pH value 5.5. Further more, particles 
are more likely to form aggregates comparing with that at low pH value 4.2. In the case of high pH, the 
aggregation of CSNPs mainly distributes to wide size distribution. On the other hand, at high mass ratio 
of chitosan to TPP 5:1, PDI increases from 0.27±0.01 at pH 5.5 and 0.25 at pH 4.2 to 0.34±0.04 at pH 3. 
At the same mass ratio of chitosan to TPP 4:1, the PDI of CSNPs increased from 0.27±0.02 to 
0.39±0.01 when pH value was adjusted from 4.2 to 3. As shown in inset B (size distribution of CSNPs 
prepared at pH 4.2) and C (pH 3) in Fig.2.5, more small particles generated at pH 3 comparing with 
that at pH 4.2. Therefore, as shown in Fig. 2.5, pH value and mass ratio of chitosan to TPP collectively 
define an area in which formed CSNPs having a narrow size distribution. Otherwise, out of this area, 
wide size distribution could happen to CSNPs in the form of aggregation or a big number of small 
particles. Calvo et al. found in their research that CSNPs could only form in specific concentration 
range of chitosan and TPP [98]. In addition, Fan et al. found that when pH was below 4.5, it was not 
easy to produce nanoparticles with unimodal particle size distribution, while when pH was above 5.2, 
micro-particles were unavoidable present in suspension [109]. The above result in this study is 
generally in agreement with their data.  
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Fig. 2.5 The Effect of pH on Particle Size Distribution of Chitosan Nanoparticles. A, B, and C, the 
size distribution by intensity (light intensity in the unit of % against size in nanometer) of CSNPs 
prepared at pH 5.5, 4.2, 3.0 respectively (mass ratio of chitosan to TPP=4:1). The numbers in dash line 
squares are polydispersity indexes (PDI) of nanoparticles. ▼: Aggregation. 
 
The Effect of pH on the Encapsulation Efficiency of Chitosan Nanoparticles 
Chitosan molecules are positively charged in acetic medium. Therefore, they commonly used as 
carrier material to entrap or incorporate negatively charged macromolecules. In this study, BSA with an 
isoelectric point of 4.7 was used as model protein to investigate the effect of pH on the encapsulation 
efficiency (EE) of CSNPs. Since chitosan has a pKa of 6.5, 3 pH values (5, 5.5, 6) were set in the range 
of 4.7~6.5 to make electrostatic reaction happen between chitosan and BSA molecules.  
As shown in Table 2.3, both particle size and PDI of CSNPs increased with the increasing solution 
pH value. However, when solution pH increased to 6, the resulting particles suspension was no longer 
stable. Aggregation of particles appeared which made only a part of small particles stay in suspension 
according to the size measurement. Gan et al. [110] studied the effect of solution pH on the particle size 
of CSNPs with raw chitosan by directly adjusting the pH of resulting particles suspension. They found 
a sharp increase of particle size of CSNPs at pH>6. In their further study on the surface charge density 
of CSNPs, particles showed a continual decrease in the positive zeta potential well before the pH value 
reached pH 6.0. Therefore, they concluded that deprotonation of the particle surface at pH > 6.0 
induced decreasing electrostatic repulsion between particles thereby increasing the probability of 
particles aggregation. In this study, the particles aggregation happened at pH 6 may follow the same 
mechanism suggested by Gan et al..  
After loading BSA, CSNPs showed a significant change in particle size, but no regular trends. It is 
difficult to interpret the influence of BSA encapsulation on particle size of CSNPs, because both the 
electoral states of chitosan and BSA molecules are changing with pH value. However, the particle size 
and size distribution of BSA-incorporated CSNPs (BSA-CSNPs) showed remarkable increase with the 
increasing pH value. Therefore, on the particle size point of view, the particle size of BSA-CSNPs 
increased as pH value increased, which suggests that pH value played a predominant role compared 
with BSA. With respect to size distribution, TPP cross-linked chitosan nanoparticle is actually one state 
of chitosan-TPP binary electrolyte system under specific conditions [113]. In the pH range of this study, 
negatively charged BSA molecules competed with TPP ions to electrostaticly react with chitosan. The 
shielding effect of counter ions, BSA molecules, disturbed the polymer network formed by chitosan 
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and TPP, which consequently reduced the monodispersity of CSNPs. 
Table 2.3 Particle Size and Size Distribution of CSNPs/BSA-CSNPs Formed at Various pH 
Values. 
Particle Size 
(nm)/PDI CSNPs BSA-CSNPs 
5.0 337.1±7.3/0.28 300±4.8/0.26±0.01 
5.5 381.2±5.8/0.32±0.04 499.2±18.7/0.49±0.03 
pH 
6.0 250.6±5.8/0.28±0.01
※
450.1±15.4/0.55±0.07
※
 
※: At this pH value, particles suspension was unstable and aggregates were present. 
  As shown in 2.6, pH value has a clear effect on the BSA encapsulation efficiency (EE) of CSNPs. 
The EE of CSNPs increased dramatically from 52% at pH 5 to 66% at pH 5.5 and almost 100% at pH 6. 
The increase of EE could be contributed to two effects induced by solution pH. Firstly, BSA molecules 
are further negatively charged with the increasing pH value, which favors the electrostatic reaction 
between chitosan and BSA molecules and consequential higher EE. On the other hand, particle size of 
CSNPs increased with the increasing solution pH, which improved the BSA encapsulating capability of 
particles.  
 
Fig. 2.6 The Influence of pH on BSA Entrapment Efficiency of CSNPs.  
 
The Effect of TPP Solution pH on the Properties of Chitosan Nanoparticles 
Chitosan is a cationic polymer which can form particles with negatively charged multivalent anions, 
such as sulfate [114], TPP [2]and deoxycholate [115], biomacromolecules such as DNA[116], siRNA 
[117] , lecithin [118] or polymers such as dextran sulphate [119], alginate [120] and hyaluronic acid 
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[121]. In addition, the deprotonation of charged amino groups on chitosan chains can results in 
precipitation of chitosan from aqueous solution and consequently leads to the formation of chitosan 
particles as well [122]. Mi et al. [123] reported TPP solution with different pH value could form 
chitosan beads with different interior structures via the coacervation effect of hydroxyl ions and ionic 
cross-linking of TPP ions. In this study, the effect of TPP pH value on the formation of chitosan 
nanoparticles is studied. Since the original TPP solution has a pH value around 9.5 in which OH- and 
TPP ions coexist, the original TPP solution and a pH 5.5 TPP solution were chose to prepare CSNPs. 
The pH value of chitosan solution was set at 5.5. 
As shown in Table 2.4, the CSNPs obtained with pH 9.5 TPP (9.5 blank) showed a bigger particle 
size, but a wider particle size distribution than that of CSNPs obtained with pH 5.5 TPP (5.5 blank). 
This could be interpreted that OH- ions more easily penetrate chitosan gel matrix due to their smaller 
size compared with TPP ions, thus large amount of OH- ions in pH 9.5 TPP solution induced the bend 
of chitosan chains firstly, consequently more intermolecular chitosan-TPP linkages formed, and 
eventually bigger particles generated. Meanwhile, the conjunct roles of OH- and TPP on chitosan 
matrix result in nonhomogeneous and ionicly cross-linked particles [123]. Besides, 9.5 blank also has a 
bigger yield than that of 5.5 blank. The incorporation of BSA increased the particle size of CSNPs 
obtained with pH 5.5 TPP and polydispersity index (PDI) as well. However, for BSA-incorporated 
CSNPs obtained with pH 9.5 TPP (9.5 BSA), the incorporation of BSA make particles suspension 
unstable to precipitate out. Compared with 5.5 BSA, 9.5 BSA showed a higher yield and BSA 
encapsulation efficiency (EE). In the case of 9.5 BSA, even all of BSA was incorporated.  
Table 2.4 The Properties of Chitosan Nanoparticles and BSA-incorporated Chitosan 
Nanoparticles. 
Particle Size (nm) PDI Yield (%) EE (%) 
 
9.5 5.5 9.5 5.5 9.5 5.5 9.5 5.5 
CSNPs 495.3±21.7 386.4±8.6 0.46±0.05 0.27±0.04 36±4 30.7±2.3 - - 
BSA-CSNPs ※ 433.8±5.7 ※ 0.43±0.04 29.5±1.6 27.6±3.3 100 71.7±0.5
※: Particles suspension was unstable and aggregates were present. 
The obtained CSNPs and BSA-CSNPs were further characterized by FTIR-AIR spectrometry, DSC 
analysis and SEM. As shown in Fig. 2.7, chitosan hydrochloride (CSCL) showed characteristic 
absorbance peaks at 1632 cm-1 and 1514 cm-1 which indicate to the C=O stretching vibration of amide I 
and  –NH stretching vibration of amino groups as reported previously [124]. The absorbance peaks of 
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BSA at 3282, 1644, and 1515 cm−1 are assigned to the stretching vibration of –OH, amide A (mainly 
–NH stretching vibration), amide I (mainly C=O stretching vibrations), and amide II (the coupling of 
bending vibrate of N–H and stretching vibrate of C–N) bands, respectively [125].  
After the formation of 2 blank CSNPs and 2 BSA-CSNPs, the peak at 1514 cm-1 in CSCL shifted to 
1535 cm−1. The peak at 1624 cm-1 in CSCL shifted to 1632 cm-1 in 2 blank CSNPs. Besides, a new 
absorbance peak at 1204 cm-1 which indicates P=O stretching [126] shows up in the spectrum of all the 
4 CSNPs. These suggest the amino groups on chitosan and TPP are involved in the formation of CSNPs. 
The absorbance peaks at 3282 cm-1, 1644 cm-1 which are the characteristic absorbance peaks of BSA 
and the peaks at 1535 cm-1, 1204 cm-1 which are assigned to CSCL are present in the 2 BSA-CSNPs. 
This suggests the encapsulation of BSA into CSNPs.  
 
Fig. 2.7 FTIR Spectrums of Chitosan Nanoparticles and BSA-incorporated Chitosan 
Nanoparticles.  
In order to understand the thermal behaviors of CSNPs ionicly cross-linked by TPP at different pH 
values, DSC analysis was performed. Fig. 2.8 shows the thermograms of CSCL, BSA, lyophilized 
CSNPs and BSA-CSNPs (the third thermal scan). Not like chitosan, the DSC curve of CSCL shows a 
wide endothermic peak centered at 228 ℃ which could be registered as the Tm of CSCL. The DSC 
curve of BSA shows a characteristic endothermic peak at about 222 ℃ [127]. Compared with CSCL, 
a wide endothermic peak centered around 235 ℃  with an onset at 187 ℃  appeared in the 
thermograms of 5.5 blank and 5.5 BSA which can be attributed to the breakdown of weak electrostatic 
interaction between chitosan and TPP [128]. Compared with 5.5 blank, this endothermic peak of 5.5 
BSA shows a slightly bigger enthalpy change (ΔH). Further more, the exothermic peak of 5.5 BSA is 
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centered at a slightly higher temperature than that of 5.5 blank. These probably suggest a weak 
electrostatic interaction exist between BSA and chitosan. In addition, 5.5 BSA shows a wider 
exothermic peak comparing with 5.5 blank, which may be contributed to relatively inhomogeneous 
crystalline arrangement resulted from the encapsulation of BSA. This is also in agreement with that 5.5 
BSA have a wider particle size distribution than that of 5.5 blank.  
Intriguingly, two exothermic peaks appeared in the DSC curve of 9.5 blank, which suggests two 
crystalline arrangements exist in sample. Similar result also was previously reported by Liu et al. [128]. 
As shown in Fig. 2.8, one of the two exothermic peaks in 9.5 blank and 9.5 BSA is centered at a nearby 
temperature with that of 5.5 blank and 5.5 BSA. It suggests that similar crystalline arrangement exists 
in the CSNPs ionicly cross-linked by TPP at different pH values. Beside of this exothermic peak at 
around 260 ℃, another exothermic peak exists in the DSC curves of 9.5 blank and 9.5 BSA and is 
centered at lower temperature. Further more, the ΔH of this peak in 9.5 blank and 9.5 BSA is bigger 
than the peak centered at 260 ℃. It indicates the crystalline arrangement which refers to the peak 
located at relative low temperature has a predominant proportion in 9.5 blank and 9.5 BSA. In addition, 
both of the DSC curves of 9.5 blank and 9.5 BSA show a quite wide endothermic peak which is distinct 
with that of 5.5 blank and 5.5 BSA. It probably implies 9.5 blank and 9.5 BSA have less intensive 
chitosan-TPP linkages than that of 5.5 blank and 5.5 BSA.  
In a weakly acetic environment, both of tripolyphosphoric and hydroxyl ions are present in 
chitosan-TPP gel system. But, the hydroxyl ions preferentially bind to NH3+ binding sites on chitosan 
chains due to the their higher mobility compared with tripolyphosphoric ions, which causes polymer 
chain softens considerably [13]. In this study, the big amount of OH- ions in pH 9.5 TPP solution soften 
chitosan polymer chains via the deprotonation of NH3+ resides, consequently leads to the folding of 
chitosan chains. In this way, less tripolyphosphoric ions are involved in the electrostatic interaction 
with chitosan. Further more, more ionic linkages are formed between folded chitosan molecules. 
However, as indicated by DSC analysis, there are still some crystalline arrangements which are similar 
with what could also found in CSNPs corss-linked by pH 5.5 TPP solution. One possible explanation to 
this phenomenon is that the CSNPs cross-linked by pH 9.5 TPP solution (pH5.5 blank and 9.5 BSA) 
are not completely cross-linked by TPP ions due to the folding of chitosan chains results from the 
deprotonation of OH- ions. To be detailed, the folding of chitosan chains may hinder tripolyphophoric 
ions diffusing into the very center of particle gel matrix. Consequently, particle center is not fully 
cross-linked by TPP ions. The other explanation is that tripolyphosphoric and hydroxyl ions conjointly 
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play roles on the formation of chitosan nanoparticles, which induce the nonuniformity of particles. 
However, in regardless of which reason inferred above, the relatively loose chitosan matrix which is 
cross-linked by relatively fewer TPP ions in the case of TPP solution at higher pH results in high BSA 
encapsulation.  
 
Fig. 2.8 DSC Thermograms of CSNPs and BSA-CSNPs.  
  In order to verify the above inferred reasons, the morphology of chitosan nanoparticles was checked 
using SEM. As shown in Fig. 2.9 A and C, particles in 9.5 blank and 9.5 A are irregular-shaped, loose 
and inhomogeneous. On the contrary, as shown in B and D, particles in 5.5 blank and 5.5 BSA are 
nearly spherical, compact and homogeneous. The compact particles formed with pH 5.5 TPP solution 
are also in accordance with the interpretation proposed in the first section. That is, more extended 
chitosan chains form more compact particles at low pH value. Since many small particles are also 
present in 9.5 blank and 9.5 BSA, the latter interpretation discussed in DSC analysis part seems more 
reasonable. That is, tripolyphosphoric and hydroxyl ions conjointly affect the formation of chitosan 
nanoparticles, which could result in the nonuniformity of particles. 
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Fig. 2.9 SEM Microphotographs of CSNPs and BSA-CSNPs Cross-linked by TPP at Different pH 
Value. A, 9.5 blank, B, 5.5 blank, C, 9.5 BSA, D, 5.5 BSA. Scale Bars represent 1 μm. 
The FTIR spectrometry confirms the encapsulation of BSA into chitosan nanoparticles. The DSC 
analysis confirms the electrostatic interaction between CSNPs and BSA molecules, even though this 
interaction is weak. Seen from the SEM photographs of BSA-incorporated CSNPs, the encapsulation of 
BSA gives CSNPs ununiformity. In other words, a charged biomolecules—BSA disturbed chitosan-TPP 
gel system and make the situation more complicated. As seen above, higher solution or TPP solution 
pH gives higher BSA encapsulation efficiency. Here, we studied the in vitro BSA release profiles of 
two BSA-CSNPs cross-linked by TPP solutions at different pH values.  
As shown in Fig. 2.10, 5.5 BSA shows an initial burst release in the first hour in pH 7.4 PBS at 37 
℃ followed by a slow release in the following 24 hours. Gan et al. [129] investigated the in vitro 
release of BSA from CSNPs. They concluded that the burst is more likely a consequential effect of 
rapid surface desorption of large amount of protein molecules from a huge specific surface area 
provided by large numbers of particles at nano-scale, and a larger proportion of protein molecules may 
not truly embedded in the nanoparticles’ inner structure. Compared with 5.5 BSA, 9.5 BSA only 
released ~20% of BSA in the first hour and then a sustained release in the next 6 hours. However, 
totally only <70% BSA were release after 24 hours. It is probably contributed to two reasons. On one 
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hand, 9.5 BSA have a big particle size which extends the diffusion pathway of BSA molecules. On the 
other hand, the bending conformation of chitosan chains under this condition may hinder the diffusion 
of BSA molecules in particles. In this sense, for 5.5 BSA, their polymer chains are more extended, 
which provide more NH3+ binding sites for TPP. Therefore, more compact polymer network forms for 
particles. Since BSA molecules also have a large dimension (an ellipsoid of revolution with major and 
minor axes 13.8 and 4.6 nm) [130], compact internal structure may limit the distribution of BSA 
molecules inside particles. Eventually, most of BSA molecules absorb on particle surface, which results 
in an initial burst release effect. 
 
Fig. 2.10 The in vitro BSA Release of BSA-CSNPs. TPP 9.5/TPP 5.5, BSA-CSNPs gelated by pH 
9.5/5.5 TPP solution. The pH value of chitosan solution was 5.5 for the both cases. 
2.3.5 VEGF-incorporated CSNPs for the Regeneration of Peripheral Nerves 
In this section, VEGF-incorporated CSNPs are prepared to preserve the bioactivity and control the 
release of VEGF in a hydrogel for peripheral regeneration. The particle size and yield of blank CSNPs/ 
VEGF-CSNPs are shown in Table 2.5. Figure 2.11 shows the particle size distribution of blank CSNPs 
and VEGF-CSNPs. VEGF-CSNPs show smaller particle size in comaprison with that of blank CSNPs. 
It suggests that the incorporation of VEGF disturbed the formation of CSNPs. The obtained particles 
were observed under TEM (see Figure 2.12). At the chitosan (LMWCS) concentration of 2 mg/ml, 
CS/TPP mass ratio of 3/1 and solution pH 5, nanoscale coacervates form and are prone to fuse with 
each other (see Figure 2.12A). At high magnification, small particles are visible inside the coacervates 
(see Figure 2.12B). For VEGF-CSNPs, no particles with size above 100 nm in disagreement with the 
particle size data based on DLS. Probably because coacervates formed at this preparation conditions. 
This coacervates could be detected by DLS in solution, but could not be seen by TEM at the dry 
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environment. A few small nanoparticles are visible (see Figure 2.12C),with deep color in the core and 
on the surface (in accordance to what Fan et al. observed [131]). Besides, small pieces of irregular 
shaped coacervates are present in the whole picture. However, the in vitro release of VEGF-CSNPs 
showed a rapid initial burst release effect (see Figure 2.13). The burst release effect results from the 
week electrostatic interaction between VEGF molecules and CSNPs. Since chitosan is a cationic 
polymer, negatively charged protein molecules are supposed to be encapsulated more efficiently. 
Whereas, VEGF is a basic protein molecule with an isoelectric point of 8.5. This may explain why 
VEGF-CSNPs show a burst release effect of VEGF.  
Table 2.5 Particle size and Yield of VEGF-CSNPs. 
 Particle Size (nm) PDI Yield (%) 
Blank CSNPs 281.6±6.1 0.22±0.02 78.9±5.3 
VEGF-CSNPs 250.1±3.2 0.20±0.04 87.7±3.0 
 
 
Fig. 2.11 Particle Size Distribution of CSNPs/VEGF-CSNPs. 
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Figure 2.12 TEM Photographs of CSNPs and VEGF-CSNPs. A, CSNPs, B, CSNPs at High 
Magnification, C, VEGF-CSNPs. Green arrows indicate nanoparticles. 
 
Figure 2.13 The in vitro release of VEGF from VEGF-CSNPs. Performed by Francesca Ruini and Chiara 
Tonda Turo. 
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2.4 Conclusion and Perspective 
  In this chapter, chitosan nanoparticles are prepared for the delivery and controlled release of protein 
molecules. The main factors which affect the particle size, protein loading and release properties of 
CSNPs are studied. Increasing polymer concentration, particle size of CSNPs increases, but a wider 
size distribution is obtained. Protein encapsulation efficiency rises with increasing CS concentration, 
but only in the CS concentration range above 2.5 mg/ml. When CS/TPP mass ratio increases, that is, 
when TPP decreases, particles yield decreases, but particle size increases. Thus, the presence of smaller 
particles results in the decrease of particles EE. The presence of BSA shows an influence on the 
particles formation. The particle size data reveals that TPP plays a dominant role on the formation of 
CSNPs at the CS/TPP mass ratio 3/1. When this ratio goes up, BSA starts to affects the particle size 
more than CS/TPP mass ratio.Consequently, particle size and size distribution stop increasing 
remarkably. It can be attributed to the competitive interaction between BSA molecules and TPP ions 
with chitosan. BSA concentration does not significantly affect particles yield and size. A decrease in 
particles EE when BSA concentration increases from 0.5 to 1.5 mg/ml is detected. Kaloti et al indicated 
that phase transition was involved in the chitosan-TPP polyelectrolytes system [132]. Therefore, the 
effect of these parameters on the size and drug encapsulation of CSNPs should take this issue in 
consider.  
This work studied the effect of pH value on the formation of TPP-ionic-gelated chitosan 
nanoparticles and protein its encapsulation efficiency. To be different with previous studies, this study 
studied the influence of pH value on the formation of chitosan nanoparticles considering both the pH 
values of chitosan and TPP solution. In order to do this, the pH of ionic cross-linker—TPP was adjusted 
to the same value to that of chitosan solution. In addition, the influence of TPP pH on the formation of 
CSNPs and its protein encapsulation efficiency were also studied. Thus, this study is favorable to better 
understand how to get monodispersed chitosan nanoparticles, how to achieve a high protein 
encapsulation efficiency and how to prolong the release of protein from chitosan nanoparticles. 
Firstly, pH value has a significant effect on the particle size of CSNPs. The lower pH value is, the 
smaller the particle size is. This because chitosan chains are more extended at lower pH value due to 
the protonation of amino groups on chitosan chains. Under this condition, more NH3+ are exposed to be 
cross-linked by tripolyphosphoric ions, consequently more compact chitosan polymer network forms 
and eventually smaller particle size is achieved. In comparison with the mass ratio of chitosan to TPP, 
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pH value plays a predominant role on particle size. Nevertheless, pH value affects particle size 
distribution of CSNPs along with this ratio. It is found that monodispersed CSNPs only form in a 
domain which is defined by pH value and mass ratio of chitosan to TPP. Under the conditions which 
are outside this domain, CSNPs are unstable with a big size distribution or aggregates.  
BSA was used as a protein model in this study. Various pH values which fell in the pH range 
between the Ip (~4.7) of BSA and pKa (~6.5) of amino groups on chitosan were set for BSA 
encapsulation experiments. Both the particle size and size distribution of CSNPs and BSA-incorporated 
CSNPs increased with the increasing pH value. However, when pH value retched 6, particles 
suspension became unstable. In addition, in comparison with blank CSNPs, the influence of BSA 
encapsulation on particles size of BSA-CSNPs did not follow any certain roles, which probably 
because the electrical states of all the components in chitosan-TPP gel system could be affected by 
solution pH. Even so, the encapsulation efficiency of CSNPs increased dramatically when pH value 
increased. This could be contributed to the larger particle size at higher pH, which makes encapsulating 
more BSA possible. This could be also contributed to more negative charges BSA molecules bear at 
higher pH, which leads to stronger electrostatic attraction between BSA and chitosan. 
In the end, the effect of TPP solution pH on the properties of chitosan nanoparticles was studied. 
Two TPP solutions at different pH were used: one original TPP solution at pH 9.5 and the other tuned to 
pH 5.5 which was the same with that of chitosan solution used for both cases. Results indicated that 
chitosan nanoparticles prepared with pH 9.5 TPP solution had a bigger particle size, wider size 
distribution, higher yield and BSA encapsulation efficiency comparing with that of particles prepared 
with pH 5.5 TPP solution. FTIR microscopy proved the formation of particles and encapsulation of 
BSA, but did not reveal any reaction between chitosan and BSA. The further thermal analysis of two 
particles with DSC revealed that two crystalline arrangements existed in the particles prepared with 
TPP 9.5 TPP solution. Together with SEM analysis in which 9.5 blank and 9.5 BSA particles showed 
irregular-shaped, ununiform, and loose appearance, we concluded that hydroxyl ions and 
tripolyphophoric ions conjointly reacted with chitosan chains (see Fig. 2.14). Since DSC result revealed 
that BSA had a weak electric reaction with chitosan, here, the conformation of chitosan chains played a 
predominant role in the formation of chitosan nanoparticles and BSA encapsulation. As shown in Fig.7, 
when an acetic TPP solution is used to cross-link chitosan, chitosan chains can hold the extended state 
thereby a compact chitosan polymer network which is fully cross-lined by TPP ions forms. In this case, 
considering the dimensions of chitosan nanoparticles and BSA molecules, a big amount of BSA 
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molecules would rather absorb on the particle surface than are entrapped inside particles, which is also 
verified in BSA release profile in this study. For the case of chitosan nanoparticles prepared with a 
basic TPP solution, tripolyphosphoric ions react with chitosan along with hydroxyl ions. Nevertheless, 
hydroxyl ions preferentially react with chitosan via deprotonizing NH3+ on chitosan due to their high 
mobility. The deprotonation of NH3+ not only softens chitosan chains but also decreases the number of 
NH3+, which results in few and far ionic linkages between chitosan and TPP. Therefore, large, loose and 
inhomogeneous particles are obtained as seen under SEM. However, a small amount of small particles 
inevitably generate as well, since both hydroxyl ions and tripolyphosphric ions are present, which is 
also the reason why two crystalline arrangements were detected by DSC analysis in this study. In this 
case, loose and large particles are capable to encapsulate a big amount of BSA molecules. Further more, 
the big particle size also provide a long distance diffusion path for encapsulated BSA molecules and in 
sequential a sustained release of BSA.  
 
Fig. 2.14 Schematic Presentation of Chtisan Nanoparticles Cross-linked by TPP with Different 
pH Values.  
To sum up, in order to obtain monodispersed chitosan nanoparticles, an acetic TPP solution should 
be used to cross-link chitosan; in order to achieve a high protein encapsulation efficiency, an as high as 
possible pH value should be adopted; in order to achieve a long and sustained protein release, the 
dimension of protein molecules and the effect of pH value on the formation of chitosan chains should 
be taken into account. 
VEGF is intended to be encapsulated into chitosan nanoparticles to preserve its bioactivity and 
realize stable release in a chitosan/gelatine blend hydrogel. The in vitro release profile of this 
VEGF-CSNPs shows a initial burst release in a few hours. The electric state of VEGF is very likely to 
be responsible for this phenomenon in the consideration of CSNPs are preferable to carry anionic 
drugs. 
 51
The nature of the structures visible (Fig. 2.10A and C) in the CSNPs gelated by pH-untuned TPP is 
not completely clear, The possibility that the irregular-shaped blocks are aggregates of small CSNPs 
can be excluded, because if they were, the temperature of their exothermic peak should be located at 
higher temperature which is not the case. It can be also supposed that these are the result of the gelation 
of different tripolyphosphic ions (P3O105−, H2P3O103−, and HP3O104−), since in any pH range three forms 
of ions coexist in TPP solution. This possibility is not strongly supported, because all these ions have 
equal chances to react with chitosan, thus it is not likely  to get two crystal structures. The most 
reasonable explanation is that these blocks are the result of coacervation induced by hydroxyl ions in 
pH-untuned (~9.5) TPP solution. Chitosan particles coacervates by other salts e.g. Na2SO4 are usually 
irregular-shaped. For this reason, a control experiment could be set to confirm the .  
Even through the advantage of TPP gelated CSNPs in encapsulating bioactive molecules, its fast 
release profile could be a barrier for certain applications. For this reason, several other chitosan based 
derivatives have been proposed to overcome this drawback. For instance, thiolated chitosan which can 
be used to cross-link chitosan via covalent bonds could be a means to achieve a more sustainable 
release [133]. On the other hand, alternative drug encapsulation strategies can be also considered. For 
example, microemulsion containing interior chitosan aqueous phase can be formulated to entrap the 
drug [134]. During the study of section 3.3.5, when pH value of the mixture of TPP and BSA came to 
2~3, the mixture started to become turbid. Some of this suspension was checked by SEM and 
coacervate complexes were visible. In order to exclude the possible formation of salt crystals, 
controlled trials were performed. NaCl (HCl was used to tune solution pH) and TPP solution were 
deposited to undergo SEM observation. Results indicated that no such regular complexes could be 
visible in NaCl and TPP samples (see Appendix 4). The controlled trials of individual titration of BSA 
and TPP solution are also negative (data not shown). Afterwards, a set of BSA/TPP mass ratios were 
adopted to obtain monodispersed BSA/TPP coacervate complexes. As shown in Figure 2.16, single 
nanoscaled BSA/TPP coacervates are already visible at BSA/TPP mass ratio 2/1. If the solution pH was 
tuned back to a neutral or basic pH value, this complex form redissolved into solution, but not in pure 
water. Thus, this BSA/TPP coacervate complex provided a possible way to more effective BSA 
encapsulation. As shown in Figure 2.15, a considerable amount of BSA is entrapped in subsurface layer 
of chitosan particles and able to diffuse out of particle quickly. Whereas, if BSA molecules were 
condensed as the particles core covered by a layer of polymer shell as shown in the right model, this 
diffusion course could be prolonged. Considering the electric state of BSA/TPP coacervate complex, an 
 52
anionic shell material e.g. alginate could be alterative. 
 
Fig. 2. 15 The Schematic of BSA Encapsulation Form by CSNPs. 
 
 
Fig. 2.16 The BSA/TPP Complex Formed at Low pH Value. The mass ratio of BSA/TPP of A), B), 
and C) is 2/1, 3/1, 5/1 respectively. Magnification: 10, 000X. 
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Chapter 3 Chitosan Microparticles for the Controlled Release of 
Proteins 
3.1 Aim of the Study 
  In this section, CSMPs were prepared to realize prolonged and stable protein release based on 
conventional emulsification and coacervation method. Since particle size, homogeneity and surface 
morphology significantly affect the protein loading and release properties, a set of preparation 
parameters are systemically investigated to understand their effects on these features. On the purpose to 
overcome the serious aggregation problem encountered in the preparation of TPP-gelated CSMPs, a 
microemulsion of TPP as gelation reagent are proposed. The final goal of this section is aimed to load 
CSMPs into bioengineering scaffolds to achieve the extended and stable release of tissue growth 
factors. However, organic solvents, rigorous shear forces result from homogenization used in this 
conventional method could compromise the bioactivity of protein molecules. Therefore, CSNPs 
formulated in chapter 1 are proposed to be used to encapsulate proteins due to their mold preparation 
conditions. Afterwards, these protein-incorporated CSNPs were intended to be encapsulated into 
microparticles (MPs) in which chitosan or polylactic acid would be used as particles matrix. A set of 
porous chitosan scaffolds are prepared by freeze-drying of chitosan hydrogel (pre-gelled with dibasic 
sodium phosphate at 37°C).  
3.2 Materials and Methods 
3.2.1 Materials 
  Low molecular weight chitosan (product code: 448869) with a deacetylation degree (DD) of 
75-85% and viscosity of 20-300 cP (1% in 1% acetic acid), medium molecular weight chitosan (448877) 
with a DD of 75-85% and viscosity of 200-800 cP (1% in 1% acetic acid) were ordered from Sigma. 
The molecular weight is approximately 50,000-190,000 /190,000-310,000 Da for low/medium 
molecular weight chitosan based on viscosity. Octane, Span 85, Tween 80, Na2SO4, Fluorescein 
isothiocyanate (FITC) isomer I, dibasic sodium phosphate, and other reagent grade chemicals were 
supplied by Sigma. The information on other materials can be found in section 2.2.1. 
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3.2.2 Instruments 
  Homogenizer (ULTRA-TURRAX T.25 BASIC) was purchased from IKA Corporation. 
Fluorescence spectrometer is the product of Perkin Elmer Corporation. Fluorescence microscope 
(Axiovert 40) is the product of Zeiss Corporation. The information of other instruments could be found 
in section 2.2.2. 
3.2.3 Methods 
Preparation of Chitosan Microparticles 
Chitosan microparticles (CSMPs) were prepared according to an emulsification and ionotropic 
gelation method adopted by L. Y. Lim et al. [135] with some modification. In brief, low/medium 
molecular weight chitosan was completely dissolved in water containing 1% (v/v) acetic acid to a 
concentration of 2% (m/v). Two milliliters of a chitosan solution were added into 20ml octane 
containing 4% Span 85 as emulsifier under constant homogenization at 5 Krpm for 5 min to get a 
homogeneous emulsion. Then 2ml 1 M NaOH solution was added to resulting emulsion with extended 
homogenization for 10 min. In order to study the influence of preparation conditions on the formation 
of CSMPs, various parameters such as concentration of chitosan, BSA, Span 85, stirring rate etc. were 
applied, meanwhile, the other parameters were fixed (for section 3.3.1-3.3.4, the preparation parameters 
of CSMPs were presented in Table 3.1). The resulting particles suspension was centrifugation at 3000 
rpm for 10 min at room temperature. After discarding the supernatant, particles sediment was washed 
repeatedly by acetone to remove the residual octane solvent. This washing step was repeated with water 
to remove residual salts. Finally, the obtained CSMPs were vacuuming dried at room temperature. 
Table 3.1 Preparation Parameters of Chitosan Microparticles. 
Sample 
Code 
Chitosan 
Concentration 
(%) 
w/o 
Volume 
Ratio 
Span 85 
Concentration 
(%) 
Homogenization 
Speed (Krpm) 
Times of 
Addition1 
Coacervation 
Agent 
Emulsifier 
Chitosan 
Molecular 
Weight 
BSA 
Incorporation 
(%) 
A 1 2/10 4 5 3 NaOH Span 85 
LMW 
0 
B 2 2/10 4 5 3 NaOH Span 85 
LMW 
0 
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C 3 2/10 4 5 3 NaOH Span 85 
LMW 
0 
D 2 1/10 4 5 3 NaOH Span 85 
LMW 
0 
E 2 3/10 4 5 3 NaOH Span 85 
LMW 
0 
F 2 2/10 2 5 3 NaOH Span 85 
LMW 
0 
G 2 2/10 6 5 3 NaOH Span 85 
LMW 
0 
H 2 2/10 4 8 3 NaOH Span 85 
LMW 
0 
I 2 2/10 4 10 3 NaOH Span 85 
LMW 
0 
J 2 2/10 4 5 1 NaOH Span 85 
LMW 
0 
K 2 2/10 4 5 5 NaOH Span 85 
LMW 
0 
L 2 2/10 4 5 3 Na2SO4 Span 85 
LMW 
0 
M 2 2/10 4 5 3 TPP Span 85 
LMW 
0 
N 2 2/10 4 5 3 NaOH T+S2 LMW 0 
O 2 2/10 4 5 3 NaOH S+S3 LMW 0 
P 2 2/10 4 5 3 NaOH Span 85 MMW 0 
Q 2 2/10 4 5 3 NaOH Span 85 LMW 0.5 
R 2 2/10 4 5 3 NaOH Span 85 LMW 1 
S 2 2/10 4 5 3 NaOH Span 85 LMW 2 
1. Adding the same volume of NaOH in 10 min. 2. 4% Tween 80 in chitosan solution. 3. Span 80/Span 85=1/1 (v/v). 
Particle Size Measurement and Morphology Observation of CSMPs 
  Fresh-made CSMPs was resuspended in acetone to dehydrate. Then one drop of CSMPs suspension 
was deposited on carbon stub followed by coating with gold before SEM observation. SEM 
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microphotographs were taken at magnification of 300X, 500X, 1000K to check mondispersity and 
5000X to study the surface morphology of CSMPs. Particle size analysis was performed using a image 
analysis software Image-Pro Plus 6.0 (version 6.0.0.260, Media Cybernics, Inc.). 50~90 particles were 
measured for every sample (as a example, see Fig. 3.1), then the size data was analyzed using Excel. 
 
Fig. 3.1 CSMPs Particle Size Analysis by Image Analysis Software. Software: Image-Pro Plus 6.0 
(version 6.0.0.260, Media Cybernics, Inc.). Sample: Sample A in Table 3.1. 
Preparation of TPP-gelated CSMPs 
  The preparation of chitosan emulsion was prepared by the same way as that of NaOH-gelated 
CSMPs. 10% TPP solution was prepared followed by tuning the pH value to 2. 2 ml of this TPP 
solution was added into 20 ml octane containing 2% Span 85 with homogenization at 15 Krpm for 5 
min to form TPP microemulsion. Then specified amount of this TPP microemulsion was added into 
chitosan emulsion prepared before with continuous homogenization at 5 Krpm for 10 min. The mixed 
emulsion was standed for 4 hours. The resulting microparticles were collected by centrifugation at 3000 
rpm for 10min. Then the obtained particles were washed by acetone and water repeatedly to remove 
residual octane and TPP followed by vacuuming dried at room temperature. 
Fluorescence Labeling of CSNPs 
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CSNPs/BSA-CSNPs were prepared according to section 2.2.3 with chitosan hydrochloride. The 
main preparation parameters are as follows: CSCL concentration 2mg/ml, CS/TPP mass ratio 5/1, BSA 
concentration 0.5 mg/ml, total reaction solution volume 98 ml, and stirring speed 600 rpm. The 
fluorescence labeling of CSNPs was performed according to the method Zhao et al. [136] described 
previously. Briefly, 0.4 mg of freeze-dried CSNPs was resuspended in 5 ml DMSO followed by the 
addition of 0.5 ml 0.1 M NaOH solution. Then FITC was dissolved in DMSO at 10.0 mg/ml 
concentration, and was slowly added to the suspension of CSNPs. The reaction between the 
isothiocyanate groups of FITC and the amino groups of D-glucosamine residue on chitosan was 
allowed to proceed for 10 hours in the dark at room temperature. FITC-labeled chitosan nanoparticles 
were centrifugated and washed with DMSO several times until the free FITC could not be detected in 
the supernatant by fluorescence spectrophotometer. 
Preparation of CSNPs-incorporated CS/PLA-MPs 
  For the preparation of CSNPs-incorporated chitosan microparticles (CSNPs-CSMPs), 4 mg 
CSNPs/BSA-CSNPs were completely resuspended in 2 ml 2% chitosan hydrochloride solution by 
homogenization. This suspension was then added to 20 ml octane containing 2% Span 85 with 
continuous homogenization at 5 Krpm for 5 min. Afterwords, 2 ml 1 M NaOH solution was added to 
gelate microparticles under extended homogenization for 10 min. The resulting microparticles were 
collected by centrifugation at 3,000rpm for 10 min, repeatedly washed by acetone and water, and 
finally vacuuming dried at room temperature. For verifying the successful incorporation of CSNPs, the 
FITC-labeled BSA-CSNPs were incorporated into CSMPs. 
For the preparation of CSNPs-incorporated PLA microparticles (CSNPs-PLAMPs), a double s/o/w 
emulsification method was used. In brief, 8 mg CSNPs/BSA-CSNPs was collected by centrifuging the 
particles suspension. Then the obtained humid particles pellet was resuspended in 4ml dichloromethane 
containing 1% PLA and 1% Span 85 by homogenization at 15 Krpm to form the first emulsion. Then 
this emulsion was added into 20 ml 4% PVA under homogenization at 5 Krpm for 10 min. The 
resulting suspension was stirred overnight to evaporate solvent. After being collected by centrifugation, 
repeated washing with 0.1% PVA and water, the resulting particles were vacuum dried at room 
temperature. 
Preparation of Chitosan Scaffold 
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  The wide pore spongy chitosan scaffold was prepared according to the method adopted by B. Yang et 
al. [137]. Low/medium molecular weight Chitosan was dissolved in 0.5% acetic acid solution under 
continuous stirring for 48 h at room temperature. The resulting solution was filtered and stored at 4°C 
for further use. Autogelling solutions were prepared by adding dropwise 0.8 ml dibasic sodium 
phosphate (500 mg/ml) into 8 ml chitosan solution underwent continuous stirring in ice bath. Finally, 
the autogelling solutions were transferred into 24-well plate (2 ml per well) and incubated at 37°C 
overnight to obtain a chitosan hydrogel. The obtained chitosan hydrogel was stored in a refrigerator at 
-80 °C for 24 h and lyophilized in a freeze dryer for 48 h. A series of chitosan scaffolds were obtained 
with various chitosan molecular weight and concentration. The three-dimensional morphology of 
chitosan scaffold was recorded with a digital camera. 
3.3 Results and Discussion 
3.3.1 The Effect of Chitosan Dispersed Phase on the Formation of CSMPs 
The Effect of Chitosan Molecular Weight on the Formation of CSMPs 
  Low molecular weight (LMWCS, 50~190KDa, 20-300 cP) and medium molecular weight chitosan 
(MMWCS, 190~310KDa, 200-800 cP) were used to prepare chitosan microparticles to study the effect 
of molecular weight on the formation of CSMPs. The mean diameter (calculated by number) of CSMPs 
prepared with LMWCS/MMWCS is 9.4±1.9 and13.6±10.5μm respectively. However, the mean 
diameter does not cover the size feature of the later due to its wide size distribution (see Figure 3.4P). A 
big number of small particles coexist along with few big particles in sample P, which is also evidenced 
on Figure 3.2P. The viscosity of dispersed phase significantly affects the particle size of emulsion 
droplets and the lower the viscosity of dispersed phase the smaller the size of emulsion droplets [135]. 
Thus, MMWCS with a higher viscosity compared with LMWCS forms CSMPs with bigger size. The 
size distribution of CSMPs depends on the energy distribution throughout the mixing vessel and the 
turbulence induced by high stirring speed gives the emulsion droplet a wider size distribution [135]. We 
speculate that the energy distribution in MMWCS emulsion system is less homogeneous than that in 
LMWCS emulsion system since bigger particles formed with MMWCS result in more turbulence, then 
wider size distribution. Deformed (Appendix 5) and hollow big particles (Figure 3.2P) were found in 
sample P which prepared with MMWCS. Besides, some smaller particles are embedded onto big 
particles (Figure 3.2P& Figure 3.3P). These probably because high viscosity of MMWCS dispersed 
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phase hinders or slows down the diffusion of gelation agent. Consequently less gelation occurs to 
interior matrix. Thereby, these big particles formed with MMWCS show weak mechanic strength.  
 
Fig. 3.2 SEM Photographs of CSMPs Prepared with Different Molecular Weight. B, low 
molecular weight (Sigma, product code: 448869) B, medium molecular weight (Sigma, product code: 
448877) P. Magnification: 1000X. Scale Bar represents 10μm in B and 20 μm in P. 
 
Fig. 3.3 The Surface Morphology of CSMPs Prepared with Different Molecular Weight. B, low 
molecular weight (Sigma, product code: 448869) P, medium molecular weight (Sigma, product code: 
448877). Magnification: 5000X. Scale Bars represent 2μm.  
 
Fig. 3.4 Particle Size Distribution of CSMPs Prepared with Different Molecular Weight. B, low 
molecular weigh (Sigma, product code: 448869), P, medium molecular weight (Sigma, product code: 
448877). 
The Effect of Chitosan Concentration on the Formation of CSMPs 
CSMPs were prepared with varying chitosan concentrations to study the effect of chitosan 
concentration on the formation of CSNPs. Figure 3.5 shows that particle size of CSMPs increases with 
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increasing chitosan concentration. Because the lower the viscosity of chitosan dispersed phase the 
smaller the chitosan emulsion droplets and the lower the chitosan concentration the lower the viscosity 
of chitosan dispersed phase, so chitosan aqueous phase with lower concentration is prone to form 
smaller emulsion droplet. Eventually CSMPs with smaller size form at the low chitosan concentration. 
This trend is also confirmed by the size analysis with software (see Figure 3.7). The particle size ranges 
of CSMPs are 3~7, 6~14, 10~50 μm and mean diameters are 4.3±0.9, 9.4±1.9, 20.1±7.1 μm with 
respect to 1%, 2% and 3% (m/v) chitosan respectively. Besides, particle size shows wider size 
distribution at high chitosan concentration. With 3% chitosan, smaller particles form compared with the 
concentration 1% and 2%. As discussed above, this wide size distribution effect of high chitosan 
concentration probably is contributing to the energy distribution in the emulsion system which is 
affected by turbulence. Nevertheless, big particles forming with high chitosan concentration are able to 
result in more turbulence than the small particles do. On the other hand, with 1% chitosan, fusion of 
particles appears. With the 1 % chitosan solution, the dispersed chitosan droplets in octane had a low 
chitosan volume, resulting in weak microparticles upon interaction with NaOH because of the 
relatively thin wall of gelled chitosan. Collision of the particles with each other may cause tearing at 
the point of contact on the weak wall, resulting in the fusion of ungelled material between the particles 
[135]. All the three CSMPs show smooth surface as seen in Figure 3.6. 
 
Fig. 3.5 SEM Photographs of CSMPs Prepared with Different Chitosan Concentration. A, 1%, B, 
2%, C, 3%. Magnification: 1000X. Scale Bar represents 20μm in A and 10 μm in B and C. 
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Fig. 3.6 The Surface Morphology of CSMPs Prepared with Different Chitosan Concentration. A, 
1%, B, 2%, C, 3%. Magnification: 5000X. Scale Bars represent 2μm.  
 
 
Fig. 3.7 Particle Size Distribution of CSMPs Prepared with Different Chitosan Concentration. A, 
1%, B, 2%, C, 3%. 
3.3.2 The Effect of Emulsification Parameters on the Formation of CSMPs 
The Effect of w/o Volume Ratio on the Formation of CSMPs 
  The mean diameter of CSMPs prepared with varying w/o volume ratio at 1/10, 2/10 and 3/10 is 
8.1±2.3, 9.4±1.9 and 9.2±2.3μm respectively. The size distribution shows no obvious change as the 
increasing w/o volume ratio and the size of most particles is in the range of 3~17μm (see Figure 3.10). 
However, w/o volume ratio influences the surface morphology of CSMPs. Rough surface (Figure 3.9) 
and deformed particles (Appendix 6) were found in sample D which was obtianed with low w/o 
volume ratio. This effect probably results from the relative big ratio of surfactant to chitosan dispersed 
phase in sample D with 1/10 w/o volume ratio compared with sample B 2/10 and sample E 3/10. Thus, 
excess of surfactant dramatically reduces the interfacial tension between oil and water phase and 
consequently results in irregular shape or rough surface of particles. 
 
Fig. 3.8 SEM Photographs of CSMPs Prepared with Different w/o Volume Ratio. D, 1/10, B, 2/10, 
E, 3/10. Magnification: 1000X. Scale Bar represents 10μm in D and B, 10 μm in E. 
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Fig. 3.9 The Surface Morphology of CSMPs Prepared with Different w/o Volume Ratio. D, 1/10, 
B, 2/10, E, 3/10. Magnification: 5000X. Scale Bars represent 2μm.  
 
 
Fig. 3.10 Particle Size Distribution of CSMPs Prepared with Different w/o Volume Ratio. D, 1/10, 
B, 2/10, E, 3/10. 
 
 
 
The Influence of Emulsifier on the Formation of CSMPs 
  In this section we studied the effect of various emulsifiers on the formation of CSMPs. Single 
surfactant or the combination of two surfactants are used. The mean diameter of Sample B with only 
Span 85 as emulsifier, Sample N with 2% Span 80 and 2% Span 85 in continuous phase, Sample O 
with 2% Tween 80 in chitosan dispersed phase and 2% Span 85 in continuous phase is 9.4±1.9, 6.5±2.4 
and 6.6±2.5μm respectively. The addition of Tween 80 in the dispersed phase results in the reduction of 
particle size and wide size distribution (see Figure 3.13N) compared with Sample B only with Span 85 
as emusifier. Tween 80 is not effective in boosting the emulsion stability, on the contrary, much fusion 
of particles and rough particle surface appear (see Figure 3.12N). For the surfactants combination of 
Span 80 and Span 85 in Sample O, the particles size is reduced but smaller particles appear compared 
to Sample B (see Figure 3.13O). The particle surface of Sample O is smooth (see Figure 3.12N). Span 
80 is also a hydrophobic surfactant but with higher Hydrophile-Lipophile Balance Number (HLB) 
compared with Span 85. The higher the HLB number the more hydrophilic the surfactant is. Thus, the 
combination of Span 80 and Span 85 with a higher HBL number reduces particle size.  
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Fig. 3.11 SEM Photographs of CSMPs Prepared at Different Emulsifier Combinations. B, Span 85, 
N, 4%Tween 85 in chitosan solution, O, 2% Span 80+2% Span 85. Magnification: 1000X. Scale Bar 
represents 10μm in B and 20 μm in N and O. 
 
Fig. 3.12 The Surface Morphology of CSMPs Prepared with Different Emulsifier Combinations. 
B, Span 85, N, 4%Tween 85 in chitosan solution, O, 2% Span 80+2% Span 85. Magnification: 5000X. 
Scale Bars represent 2μm. 
 
Fig. 3.13 Particle Size Distribution of CSMPs Prepared with Different Emulsifier Combinations. 
B, Span 85, N, 4%Tween 85 in chitosan solution, O, 2% Span 80+2% Span 85. 
 
The Effect of Emulsifier Concentration on the Formation of CSMPs 
  The mean diameter of CSNPs prepared with varying Span 85 concentration of 2%, 4% and 6% is 
9.9±2.6, 9.4±1.9, 6.3±2.8μm respectively. All the three CSMPs show good size distribution (see Figure 
3.14 and 3.16). The particle size of CSMPs decreases with increasing Span 85 concentration. This 
result is probably due to high surfactant concentration, which reduces the interfacial tension at the 
interface between dispersed phase and continuous phase and thus particles with small size form. 
However, when the surfactant concentration is too high, for example Sample G prepared with 6% Span 
85, some collapsed and deformed particles appear (Figure 3.14G). All the three CSMPs show a smooth 
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surface (Figure 3.15).  
 
Fig. 3.14 SEM Photographs of CSMPs Prepared with Different Span 85 Concentration. F, 2%, B, 
4%, G, 6%. Magnification: 1000X. Scale Bars represent 10μm. 
 
 
Fig. 3.15 The Surface Morphology of CSMPs Prepared with Different Span 85 Concentration. F, 
2%, B, 4%, G, 6%. Magnification: 5000X. Scale Bars represent 2μm.  
 
 
Fig. 3.16 Particle Size Distribution of CSMPs Prepared with Different Span 85 Concentration. F, 
2%, B, 4%, G, 6%. 
 
The Effect of Homogenization Speed on the Formation of CSMPs 
  CSMPs prepared with homogenization speed at 5, 8, 10 Krpm show a mean diameter of 9.4±1.9, 
5.0±1.5, and 3.5±1.2μm respectively. High homogenization speed e.g. Sample H and I with 8 and 10 
Krpm give a slightly wider size distribution compared with Sample B with 5 Krpm. The particle size of 
CSMPs decreases with increasing homogenization speed. This probably results from high shear force at 
high homogenization speed tears the dispersed phase into small emulsion droplets. As discussed above, 
high stirring speed results in turbulences and these turbulences induce the heterogeneous energy 
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distribution in emulsion system and eventually particles with wide size distribution form [138]. 
However, very high stirring speed results in vigorous collision between particles. Therefore, it is 
unfavorable for the formation of regular-shaped particles. As shown in Figure 3.18, with 
homogenization speed at 5 Krpm, Sample B shows very spherical appearance. Increasing the speed to 8 
Krpm (Sample H) some particles start to lose the spherical appearance (Figure 3.18H) and become 
ellipsoidal, irregularly shaped (Figure 3.17H). When the speed is increased to 10 Krpm, fusion between 
particles appears (Figure 3.18I). 
 
Fig. 3.17 SEM Photographs of CSMPs Prepared with Different Homogenization Speed. B, 5000 
rpm, H, 8000 rpm, I, 10000 rpm. Magnification: 1000X. Scale Bar represents 10μm in B and 20 μm in 
H and I. 
 
 
Fig. 3.18 The Surface Morphology of CSMPs Prepared with Different Homogenization Speed. B, 
5000 rpm, H, 8000 rpm, I, 10000 rpm. Magnification: 5000X. Scale Bars represent 2μm.  
 
 
Fig. 3.19 Particle Size Distribution of CSMPs Prepared with Different Homogenization Speed. B, 
5000 rpm, H, 8000 rpm, I, 10000 rpm. 
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3.3.3 The Influence of Coacervation Agents on the Formation of CSMPs  
The Influence of Coacervation Agents on the Formation of CSMPs 
In this section, NaOH, Na2SO4, and TPP were used as gelling agents to study their influence on the 
formation of CSMPs. However, when TPP was added to gelate chitosan emulsions, a big amount of 
aggregates formed and could not be redispersed (Sample M in Table 3.1). Aggregation also occurred 
when Na2SO4 was used as coacervation agent of CSMPs (Figure 3.20L). Particle surface observation 
indicates that fusion between particles is present throughout the whole Sample L (Figure 3.20L). We 
speculate that different formation mechanisms of particles may be underneath the gelation process with 
different coacervation agents, since hydroxyl ion is a monovalent anion, whereas sulfate and 
tripolyphosphic ions are multivalent anions. The gelation of chitosan emulsion droplets induced by OH- 
results from the deprotonation of primary amino groups on chitosan chains. Na2SO4, and TPP induce 
the gelation of chitosan emulsion droplets via the formation of ionic linkages between SO42-/P3O105- 
and amino groups on chitosan chains. Thus, residual OH- ions are not able to make the already gelated 
chitosan particles undergo further aggregation or fusion unless the CSMPs are not completely gelated 
which sometimes occurs to the non-gelated interior matrix of CSMPs. Nevertheless, multivalent 
anions- SO42-/P3O105-, are able to react with already formed CSMPs and then aggregation or fusion of 
particles occurs.  
The mean diameter of CSMPs gelated by NaOH and Na2SO4 is 9.4±1.9 and 9.1±2.1 μm respectively. 
The CSMPs gelated by NaOH and Na2SO4 show similar size and size distribution (Figure 3.22). 
 
Fig. 3.20 SEM Photographs of CSMPs Prepared with Different Coacervation Agents. A, NaOH, B, 
Na2SO4. Magnification: 1000X. Scale Bar represents 10μm in B and 20 μm in L. 
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Fig. 3.21 The Surface Morphology of CSMPs Prepared with Different Coacervation Agents. B, 
NaOH, L, Na2SO4. Magnification: 5000X. Scale Bars represent 2μm. 
 
 
Fig. 3.22 Particle Size Distribution of CSMPs Prepared with Different Coacervation Agents. B, 
NaOH, L, Na2SO4. 
 
The Influence of NaOH Adding Rate on the Formation of CSMPs 
  The addition of NaOH solution destabilizes the chitosan emulsion. In order to reduce this 
unfavorable effect, the addition rate of NaOH was studied. In 10 min, 2 ml 1 M NaOH solution was 
added all at once, 2/3 ml every 3 min and 2/5 ml every 2 min to chitosan emulsion system to prepare 
CSMPs. The mean diameter of obtained CSMPs is 6.4±2.3, 9.4±1.9, 6.3±2.2 μm respectively. In 
comparison with Sample B which is obtained by adding NaOH in 3 times, both Sample J in 1 time and 
Sample K in 5 times show wider size distribution (Figure 3.25). Figure 3.23 indicates that Sample B is 
the most discrete sample in the 3 samples. Figure 3.24 shows the surface morphology of these 3 
samples. For Sample J in which NaOH was added all at once, much fusion of particles are found. For 
Sample K in which NaOH was added 0.4ml per 2 min, all particles are irregularly shaped and show a 
rough surface. These indicate that neither too fast nor too slow addition of coacervation agent-NaOH is 
favorable to get uniform and diepersedparticles. Therefore, the NaOH adding rate of Sample B is 
adopted for the preparation of all samples. 
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Fig. 3.23 SEM Photographs of CSMPs Prepared at Different NaOH Adding Rate. J, all at once in 
10 min, B, 3 times in 10 min, K, 5 times in 10 min. The amount of NaOH solution was kept consistent. 
Magnification: 1000X. Scale Bar represents 10μm in B and 20 μm in J and K. 
 
 
Fig. 3.24 The Surface Morphology of CSMPs Prepared with Different NaOH Adding Rate. J, 1 
time in 10 min, B, 3 times in 10 min, K, 5 times in 10 min. Magnification: 5000X. Scale Bars represent 
2μm. 
 
 
Fig. 3.25 Particle Size Distribution of CSMPs Prepared with Different NaOH Adding Rate. J, 1 
time in 10 min, B, 3 times in 10 min, K, 5 times in 10 min. 
3.3.4 The Influence of Protein Encapsulation on the Formation of CSMPs  
  The monodispersity and morphology significantly affect drug encapsulation and release. In turn, 
protein encapsulation also affects the monodispersity and morphology of particles. In this section, BSA 
with 3 concentrations-0.5%, 1%, 2% were incorporated into CSMPs to study the influence of protein 
encapsulation on the formation of CSMPs. As shown in Figure 3.26, only Sample Q with a BSA 
concentration of 0.5% shows dispersed appearance. When increasing BSA concentration from 0.5% to 
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1%, many ellipsoidal particles show up and all of particle form aggregates. When BSA concentration 
increases to 2%, particle size increases, but particles are still present as aggregates. Figure 3.27 
indicates that there is no obvious difference in the surface morphology of blank CSMPs (Sample B) 
and 0.5% BSA-loaded CSMPs (Sample Q), but some cracked particles exist in the latter sample. As 
shown in Figure 3.28, Sample Q shows smaller particle size in mean diameter of 6.1±2.4 μm and wider 
size distribution compared with Sample B with a mean diameter of 9.4±1.9μm. The diameter of most 
particle are in a range of 8~13μm, 3~10μm, 5~11μm and 7~12μm for blank, 0.5%, 1% and 2% 
BSA-loaded CSMPs. Therefore, BSA encapsulation results in the decrease of particle size and 
increased size distribution.  
 
Fig. 3.26 SEM Photographs of CSMPs Prepared with Different BSA Loading Concentrations. B, 
0%, Q, 0.5%, R, 1%, S, 2%. 
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Fig. 3.27 The Surface Morphology of CSMPs Prepared with Different BSA Loading 
Concentrations. B, 0%, Q, 0.5%, R, 1%, S, 2%. 
 
 
Fig. 3.28 Particle Size Distribution of CSMPs Prepared with Different Different BSA Loading 
Concentrations. A, 0%, B, 0.5%, C, 1%, D, 2%. 
 
3.3.5 Optimization of the Preparation Condition of TPP Gelated CSMPs 
  The drug release kinetics of CSMPs coacervated by NaOH is different with that of TPP-gelated 
counterpart. The former releases entrapped drugs via swelling and erosion of particles. For the latter, 
the chitosan matrix gelated by TPP is the primary barrier on the diffusion route of the entrapped drug. 
The preparation of TPP-gelated CSMPs had the purpose to 1) avoid using NaOH as coacervation agent 
which may compromise the bioactivity of protein molecules, 2) compare the protein release property of 
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the two CSMPs to have more options when they are used in various practical applications. However, 
serious aggregation happened when TPP was used as particles coacervation agent based on the 
conventional emulsification-coacervation method (Sample M in Table 3.1). Previous literature also 
reported the same phenomenon [135, 138]. This probably results from the direct addition of TPP 
solution which destabilizes the chitosan emulsion. Previous investigations on chitosan microparticles 
usually use glutaraldehyde as crosslinker [139, 140]. Glutaraldeyhyde is a liposoluble crosslinker, 
therefore, it can diffuse into chitosan emulsion (w/o) droplets to cross-link the interior chitosan matrix. 
For this reason, usually small quantity of glutaraldehyde was added to the chitosan emulsion, thus, its 
influence on the emulsion stability is negligible. However, glutaraldehyde is toxic to human body, 
moreover it is also able to crosslink proteins since protein molecules are also rich in amino groups. For 
this reason, it is not suitable for our goal here in which chitosan microparticles are going to be used as 
protein carriers. Hereof, we proposed to prepare a microemulsion of TPP to gelate chitosan emulsion 
without disturbing emulsion stability (see the schematic in Figue 3.29).  
The preliminary experiment showed dispersed CSMPs were obtained (Figure 3.30). At the CS/TPP 
mass ratio 1/2 (Figure 3.30A) and 3/2(Figure 3.30B), only few microparticles form along with a big 
number of small particles. At the CS/TPP mass ratio 3/1 (Figure 3.30C), the number of formed 
microparticles increases, but some porous particles also exit. Figure 3.31 shows the surface 
morphology of TPP-gelated CSMPs with CS/TPP mass ratio at 2/1. The small, round, sunk parts on the 
surface of CSMPs may verify the cross-linking process of TPP-gelated CSMPs. When small TPP 
microemulsions collide with big chitosan emulsion droplet, TPP microemulsion fuses into chitosan 
emulsion droplet quickly and then cross-link chitosan matrix (Figure 3.30). There are several kinds of 
particles in the CSMPs sample prepared with CS/TPP mass ratio 3/1. As shown in Figure 3.32, Figure 
3.32A probably show an incompletely cross-linked microparticle. The cross-linking almost has been 
done in the CSMP shown in Figure 3.32B. Whereas, Figure 3.32C shows a TPP-gelated CSMPs with 
relatively small particle size. On the base of porous particles which still exist in the CSMPs sample 
gelated with a CS/TPP mass ratio 3/1, it means gelation time is not enough or the amount of TPP 
microemulsion is not enough. The small particles shown in Figure 3.30A and B are probably the result 
of big particles which did not encounter enough TPP microemulsion droplets. 
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Fig. 3.29 Schematic of Optimized Preparation of TPP-cross-linked CSMPs. 
 
 
Fig. 3.30 SEM Photographs of TPP-cross-linked CSMPs with Various Amount of TPP 
microemulsion. A, 0.5ml, B,1.5ml, C, 3ml. Magnification: 1000X. Scale bar represents 10μm in A and 
20μm in B and C. 
 
 
Fig. 3.31 SEM Photograph of TPP-cross-linked CSMPs with CS/TPP mass ratio 2/1. Scale bar 
represents 2μm. 
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Fig. 3.32 The Surface Morphology of TPP-cross-linked CSMPs with CS/TPP mass ratio 1/3. Scale 
bar represents 20μm in A and B, 2μm in C. 
 
3.3.6 The Construction of NPs/MPs Composite Particulate System for the Controlled 
Release of Proteins 
As shown in chapter 2, chitosan nanoparticles showed an unfavorable initial release effect due to 
their nanoscale size and week electrostatic reaction with protein molecules, even though they are 
superior in preserving the bioactivity of protein molecules. As discussed in chapter 3, the use of organic 
solvents and strong shear force results from high-speed homogenization could compromise the 
bioactivity of protein molecules. However, in comparison with NPs, generally MPs possess higher drug 
payload and more extended drug release course. The strategy to construct a 
nanoparticles/microparticles composite system takes the advantages of the two and minimizes their 
drawbacks to achieve at one hand a long and stable drug release course and on the other hand effective 
protection of protein bioactivity. On this purpose, the CSNPs-containing CS/PLAMPs (CSNPs-CS/PLA 
MPs) were attempted to be constructed in this section to realize prolonged and stable protein release 
profile.  
Fresh chitosan nanoparticles/BSA-incorporated chitosan nanoparticles prepared in chapter 2 with 
particle size of 389.7±6.5/432.5±6.3 nm, BSA loading capacity of 35.1±0.3% were encapsulated to 
chitosan microparticles. Chitosan microparticles were prepared according to the preparation parameters 
of Sample B (Table 3.1). As shown in Figure 3.33, chitosan nanoparticles-incorporated chitosan 
microparticles (CSNPs-CSMPs) show a smaller particle size compared with the blank CSMPs. The size 
range of blank CSMPs, CSNPs-CSMPs and BSA-CSNPs-CSMPs is 5.6±1.9, 3.7±1.1, 4.5±1.3μm 
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respectively (see Figure 3.34). As shown in Figure 3.35, all of the three particles show smooth surface. 
There is no obvious difference among blank CSMPs and the two composite particles. In order to verify 
the successful incorporation of CSNPs into CSMPs, the BSA-CSNPs were labeled with FITC. Then the 
FITC-labeled BSA-CSNPs were incorporated to CSMPs and observed with a fluorescence microscope. 
As shown in Figure 3.36, both discrete and clustered fluorescent spots are visible in composite particles. 
It indicates that BSA-CSNPs have been incorporated in CSMPs successfully. However, the distribution 
of CSNPs in chitosan microparticles is not uniform and some aggregates of CSNPs could be seen 
inside CSMPs. It’s probably due to an incomplete redispersion of CSNPs by homogenization. Figure 
3.36 also shows that the discrete CSNPs are preferentially located in the sub layer of some 
microparticles. It suggests that the interior matrix of these chitosan microparticles were not completely 
gelated. 
 
 
Fig. 3.33 SEM photographs of A, CSNP-CSMPs and B, BSA-CSNP-CSMPs. Magnification: 1000X. 
Bar represents 20μm in A and 10μm in B. 
 
 
Fig. 3.34 Particle Size Distribution of CSMPs/BSA-CSMPs. A, blank CSMPs, B, blank 
CSNPs-incorporated CSMPs. 
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Fig.3.35 SEM Photographs of Particle Surfaces. A, CSMPs, B, CSNPs-CSMPs, C, 
BSA-CSNPs-CSMPs. Scale bars represent 2μm. 
 
Fig. 3.36 The Incorporation of BSA-CSNPs into CSMPs under Fluoresence Microscope. Bar 
represents 20μm. 
 
Considering that CSNPs show a fast initial burst release once they contact with aqueous medium, 
some BSA may already leak into chitosan microparticles matrix during CSNPs dispersion in the  
chitosan phase for emulsification. Even though these BSA leaks into the CSMPs matrix and have little 
chance to get out of the peripheral chitosan dispersed phase, the leakage could compromise the protein 
activity. To avoid this, we attempted to incorporate CSNPs into PLA to form chitosan 
nanoparticles-incorporated PLA microparticles (CSNPs-PLAMPs), since the leaking effect does not 
likely happen if CSNPs are incorporated into a hydrophobic dispersed phase. The preparation procedue 
of chitosan nanoparticles encapsulated PLA composite particles is shown in Fig. 3.37. 
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Fig. 3.37 The Schematic Presentation of the Preparation of Chitosan Nanoparticles Encapsulated 
PLA Composite Particles. 
 
As shown in Figure 3.38, the obtained blank CSNPs incorporated PLA micropaticles show a mean 
diameter of 1.7±0.3 μm. The composite PLA particles have a very spherical morphology and smooth 
surface. Some small pores are present on the surface of some composite particles. Some composite are 
partially imperfect. The pores and defects observed on some composite particles are probably the result 
of the degradation of chitosan nanoparticles which distributed on the surface or surface layer of 
composite particles.  
 
Fig. 3.38 SEM Photographs of CSNP-PLAMPs. Magnification: 3000X. Bar represents 20μm. 
 
Fig. 3.39 shows the PLA composite particles under fluorescent microscope. Some bright spots can be 
seen in the frame of microparticles, which indicates the encapsulation of chitosan nanoparticles inside 
PLA external layer.  
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Fig. 3.39 Fluorescent Microphotograph of CSNP-PLAMPs. Phase contrast mode. 
 
3.4 Conclusion and Perspective 
Chitosan microparticles have found many applications as a proteins/peptides carrier for the delivery 
of therapeutic proteins/peptides via nasal, pulmonary, and parenteral administration [139]. In this 
chapter, we aim to prepare chitosan microparticles and composite particulate system to control the 
release of proteins.  
Firstly, the preparation parameters of a conventional emulsification-coacervation method which is 
used in this study for the preparation of CSMPs are studied to obtain discrete, uniform, and spherical 
chitosan microparticles. For the dispersed phase, CSMPs obtained with medium molecular weight 
show bigger particle size than that with low molecular weight. But CSMPs formed with MMWCS 
show much wider size distribution compared with that with LMWCS. As the increase of chitosan 
concentration, particle size of CSMPs increases, meanwhile, the size distribution gets wider. However, 
at the chitosan concentration of 1%, fusion of particles occurs. The effect of chitosan molecular weight 
and concentration on the particle size and dispersity of CSMPs could contribute to the viscosity of the 
chitosan dispersed phase. Many emulsification parameters could influence the characters of CSMPs. 
w/o volume ratio shows no obvious effect on the particle size but some influence on particles 
morphology. At the w/o volume ratio of 1/10, obtained CSMPs show a rough surface and deformed 
particles appear. Above this ratio, obtained particles show a smooth surface. The addition of Tween 80 
in chitosan dispersed phase does not help to stabilize the chitosan emulsion, on the contrary, rough 
particle surface and deformed particles appear. The combination of Span 85 and Span 80 as emulsifier 
with a higher HBL number reduces the particle size of CSMPs compared to only with Span 85 as 
emulsifier. The particle size of CSMPs decreases with the increasing Span 85 concentration. However, 
when it is too high (6%), some collapsed and deformed particles appear. High homogenization speed 
induces decreased particle size, but with the increase of homogenization speed, CSMPs are not able to 
keep spherical shape and begin to deform and fuse with each other. Results indicate that the multivalent 
anions are not favorable to give CSMPs good dispersity and morphology. TPP induced serious 
aggregation of particles. With Na2SO4 as coacervation agent, deformed particles and aggregate appear. 
According to the morphology of obtained CSMPs, the addition of 2/3 ml NaOH per 3 min was found 
the favorable addition rate. With either faster or slower addition, particles fusion, irregular shape or 
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rough surface appears. In the end, various amounts of BSA were encapsulated. The results indicate that 
only BSA-incorporated CSMPs with 0.5% BSA are discrete. The encapsulation of BSA reduces the 
particle size and increases size distribution of CSMPs. The ‘Sample B’ (see Table 3.1) which is always 
used as a control for other samples gives CSMPs with the best features in this study. 
In order to avoid unfavorable preparation conditions and achieve more sustainable release, a 
modified preparation method was adopted to prepare TPP-glated CSMPs. A microemulsion of TPP was 
used to coacervate chitosan emulsion to minimize the interaction with the chitosan emulsion. Results 
show that discrete TPP-gelated CSMPs could be obtained in this way. Based on the analysis of obtained 
particles, increasing the amount of TPP microemulsion and extending the reaction time are able to 
obtain more uniform CSMPs.  
In the end, a nanoparticles containing chitosan/PLA composite particulate system was realised. The 
preliminary experiments indicate CSNPs are able to be entrapped into chitosan or PLA microparticles. 
This composite particulate system which combines the advantages of chitosan nanoparticles and 
microparticles is a promising protein carrier. 
As a prospect, in the future, the NaOH coacervated-chitosan microparticles, optimized TPP-gelated 
particles would be compared to study their controlled release property of proteins. In the end, these 
microparticles and the composite particles would be loaded onto a tissue engineering scaffold (e.g. 
chitosan scaffold as shown in Figure 3.40) to realize prolonged and stable release of growth factors.  
 
Fig. 3.40 Photographs of Chitosan Scaffolds. 
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Final Conclusion and Perspective 
Chitosan (CS) is a rare cationic natural polymer. The primary amino groups on chitosan chains 
enable chitosan to interact with a big number of chemicals, biomolecules and polymers. For example, 
deprotonated amino groups interact with polyanions to form chitosan nanoparticles which is also one 
topic of this thesis. The formed chitosan nanoparticles can be used to delivery nuclear acids, peptides 
and proteins based on the electrostatic interaction between chitosan and these biomolecules. 
Additionally, the cationic and mucous permeability enhancing properties of chitosan are always used to 
develop oral, optical, pulmonary, and gastrointestinal administration formulations. Chitosan 
microparticles studied in this thesis is one of the formats in which these formulations are developed.  
In chapter 2, chitosan nanoparticles (CSNPs) were prepared by the ionic gelation of 
polyanions-tripolyphosphate (TPP) to encapsulate protein molecules. BSA was used as a model protein. 
In order to get desirable particle size, dispersity, protein loading and release properties, the effect of 
primary preparation parameters on these characters of CSNPs were studied. Particle size measurement 
results indicated that both particle size and size distribution of CSNPs increased with increasing 
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chitosan concentration and inversely with the decreasing CS/TPP mass ratio. However, BSA 
concentration did not show a clearly detectable effect on the particle size within the studied 
concentration range, but stopped the rise of polydispersity of CSNPs with increasing CS/TPP mass 
ratio. This result indicates the competitive interaction between BSA molecules and TPP with chitosan. 
There’s no obvious effect of chitosan and BSA concentration on the yield of CSNPs, but particles yield 
decreased with the increasing CS/TPP mass ratio. Besides, the encapsulation of BSA also resulted in 
the decrease of particles yield. The encapsulation efficiency (EE) of CSNPs increased with increasing 
chitosan concentration and decreased with increasing CS/TPP mass ratio. The EE of CSNPs reduced 
remarkably at the BSA concentration range 0.5~1.5 mg/ml (chitosan 3mg/ml, CS/TPP mass ratio 5/1). 
In the past few decades, tripolyphosphate (TPP)-cross-linked chitosan nanoparticles (CSNPs) have 
been widely applied for the delivery of various biomacrimolecules such as nucleic acids, peptides and 
proteins due to their mild and convenient preparation conditions. However, ununiformity and burst 
release effect are always the major drawbacks of CSNPs and limit their application to some extent. In 
this study, we investigated the effect of pH value on the formation and protein encapsulation of CSNPs. 
The results revealed that the particle size of CSNPs dropped down dramatically with the decreasing pH 
value. However, the size distribution was conjointly influenced by pH vale and the mass ratio of 
chitosan to TPP. BSA was chose as the protein model in the study. The results indicated that BSA 
encapsulation efficiency (EE) of CSNPs increased significantly with the increasing pH value. In the 
end, the influence of cross-linker—TPP pH on the properties of CSNPs was studied. The results 
showed that the CSNPs prepared with a basic TPP solution (~ pH 9.5) had larger size, higher yield and 
BSA EE compared with that of the CSNPs obtained with a acetic TPP solution (~pH 5.5). The further 
characterization with FTIR spectrometry, DSC, SEM and in vitro BSA release test revealed that TPP 
solution pH might influence the formation and BSA encapsulation via changing the conformation of 
chitosan chains. In conclusion, this study gives a glance of the formation of CSNPs and protein 
encapsulation mechanisms from the pH value point of view. Thus, it is helpful to overcome the major 
drawbacks of CSNPs as a protein nanocarrier mentioned above. 
Preliminary in vitro experiment showed a obvious initial burst release effect by VEGF-incorporated 
CSNPs. This is probably due to the electric state of VEGF in solution that hinders an efficient 
encapsulation by cationic CSNPs. 
In chapter 3, chitosan microparticles (CSMPs) were prepared to control the release of proteins. 
Firstly, the preparation parameters were studied to get desirable particle size, dispersity and 
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morphology. Results indicated that high molecular weight and concentration of chitosan dispersed 
phase formed CSMPs with big size and wide size distribution. The study on the emulsification 
parameter found that w/o volume ratio mainly affected the surface morphology of CSMPs. Low w/o 
volume ratio (1/10) resulted in a rough particle surface. The addition of another surfactant into chitosan 
dispersed phase did not help to stabilize the emulsion. A combination of Span 80 and Span 85 as 
emulsifier with a higher hydrophile-lipophile balance (HLB) number can reduce the particle size 
compared with the CSMPs only with Span 85 as emulsifier. High speed homogenization reduced the 
particle size of CSMPs, but deformed particles and aggregates began to form. The concentration of 
Span 85 as a surfactant slightly reduced the particle size of CSMPs, but at high concentration of Span 
85 particles began to deform. As gelation agents, multivalent anions SO42- and P3O105- did not give 
good monodispersity and regular shape to CSMPs. The result showed that adding NaOH solution by 
2/3 ml every 3 min, obtained CSMPs showed the best dispersity and morphology. BSA encapsulation 
resulted in a wider size distribution compared with BSA-unloaded CSMPs. Results indicated that 
dispersed CSMPs could not be obtained with a BSA concentration above 1%. Afterwards, we 
optimized the preparation method of TPP-gelated CSMPs to realize a desirable protein release. A 
microemulsion of TPP solution was proposed to gelate the chitosan dispersed phase. The preliminary 
experiments indicated that this optimization could work to obtain dispersed CSMPs. In order to avoid 
the undesirable fast burst release of CSNPs and unfavorable preparation conditions of CSMPs, chitosan 
nanoparticles were incorporated in chitosan/PLA microparticles. Preliminary experiments verified the 
incorporation of CSNPs into Chitosan microparticles.  
  In the future, the controlled protein release properties of the NaOH-coacervated and TPP-gelated 
CSMPs could be compared. The chitosan nanoparticles incorporated PLA microparticles could be 
further engineered.and the protein release properties from this composite particulate system further 
investigated. In the end, all the three-nano, micro, and nano/micro particles could be loaded onto a 
bioengineering scaffold to test their protein release properties. During the study of chitosan 
nanoparticles, we found that protein molecules (BSA) could form nanoscaled complex with polyanions 
(TPP) at low solution pH. Therefore, it is possible to construct a core-shell nanovehicle to get a more 
sustainable protein release.  
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